ClinicalTrials.gg
CompletedNCT00162266Updated Jun 1, 2012Results posted

Abatacept With Methotrexate- Phase IIB

A Phase 2 interventional study of Abatacept (BMS-188667) and Abatacept (BMS-188667) in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 57 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-01.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
524
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
11th of 63
524 · median 119
Started
2000
with 1 other
Phase 2
9 of 63
1 open now
Registered
8th of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 11th largest by enrollment, is one of 2 that started in 2000, is one of 9 in phase 2, and was the 8th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This study was conducted to assess the safety and tolerability of Abatacept combined with Methotrexate in participants with active rheumatoid arthritis (RA). The secondary objectives were to assess efficacy, pharmacodynamic marker activity, and immunogenicity of Abatacept combined with Methotrexate.

Read the detailed description

All participants who completed the 12-month double-blind study period were eligible to continue in the open-label study. Participants received placebo, Abatacept 2 mg/kg, or Abatacept 10 mg/kg in the double-blind study. Participants receiving placebo in the double-blind study were switched 1:1 to continued treatment with placebo or Abatacept 2 mg/kg. Participants receiving Abatacept 2 mg/kg or Abatacept 10 mg/kg continued at the double-blind study dosage. After results from the double-blind period became available, all participants were switched to a weight-tiered 10 mg/kg dose of Abatacept.

Open label study design: Single group assignment, Single arm, Open label,

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Double blind study phase:

  1. Males or females (not nursing and not pregnant), at least 18 years of age. Women of child bearing potential () are eligible if they are practicing effective measures
  2. Subjects must meet the criteria of the American Rheumatism Association (1987) for the diagnosis of rheumatoid arthritis and the American College of Rheumatology (1991) functional classes I, II, or III
  3. Subjects have been taking Methotrexate (10-30 mg weekly) for at least 6 months, and at a stable dose for 28 days prior to treatment
  4. Washout/drug stabilization requirements (except Methotrexate) [ must be signed before making any changes in RA therapy if those changes are solely for the purpose of this study].

    • Leflunomide or Infliximab have already been discontinued at least 60 days prior to enrollment (prior to signing of informed consent) and a total of 90 days prior to treatment. All other Disease Modifying Anti-Rheumatic Drugs (DMARDs) (except Methotrexate) have been withdrawn at least 28 days prior to treatment
    • Oral treatment has been reduced to the equivalent of 10 mg or less prednisone daily and stabilized for at least 28 days prior to enrollment
  5. Eligibility of subjects for the study is based on their disease activity and anti-rheumatic treatment at the initial visit:

    • Methotrexate monotherapy: Subject is receiving only Methotrexate, steroids, Non-steroidal anti-inflammatory drugs (NSAIDs) and will not require washout
    • Combination therapy: Subject is receiving Methotrexate in combination with another DMARD(s) and will require washout

    At entry, Methotrexate monotherapy must have a disease activity:

    • 10 or more swollen joints (66 joint count)
    • 12 or more tender joints (68 joint count)
    • C reactive protein (CRP) ≥.1 mg/dL (10 mg/L) at "Screening" visit

    At entry, combination therapy must have a disease activity (if subject does not satisfy the above):

    • 6 or more swollen joints (66 joint count)
    • 8 or more tender joints (68 joint count)
    • No restriction on C-reactive protein (CRP)

    In addition

    All subjects who were on combination therapy at entry must undergo a 28 day of DMARDs other than Methotrexate. After the washout/drug stabilization and prior to randomization such subjects must have:

    • 10 or more swollen joints (66 joint count)
    • 12 or more tender joints (68 joint count)
    • C reactive protein (CRP) ≥ 1 mg/dL (10 mg/L)
  6. Subject is willing to participate in the study and willing to sign the informed consent

Open label study phase:

  • Participants that have completed the initial short term portion (double blind) of the study

Exclusion criteria

Exclusion Criteria:

Double blind study phase:

  1. Subjects who have at any time received treatment with BMS-188667 (Abatacept)
  2. Subjects who within 30 days of the Day 1 visit have received treatment with any drug
  3. Subjects with active vasculitis of a major organ system (except for subcutaneous rheumatoid nodules)
  4. Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological, or cerebral disease. Concomitant medical conditions that in the opinion of the investigator might place the subject at unacceptable risk for participation in this study
  5. Mammogram requiring further investigation or leading to the diagnosis of a abnormality. Complete evaluation of lesion is required before initiation of dosing
  6. Subjects with a history of cancer within the last five years (other than non-melanoma skin cell cancers cured by local resection)
  7. Subjects who have a history of clinically significant drug or alcohol abuse, or admit to consumption of more than 1 alcoholic drink per day
  8. Subjects with evidence (as assessed by the investigator) of active or latent bacterial or viral infections at the time of potential enrollment, including subjects with evidence of (HIV) infection, or or C infection
  9. Subjects with any serious or chronic infections such as pneumonia, pyelo-nephritis, renal infection, chest infection with bronchiectasis, or sinusitis in the previous 3 months
  10. Subjects with active tuberculosis requiring treatment within the previous 3 years
  11. Subjects with any opportunistic infections such as herpes zoster or cytomegalovirus (CMV) within the previous 2 months
  12. Subjects with severe asthma defined as > 3 emergency room admissions in the last year or > 3 treatments with oral for asthma in the last year
  13. A history of either angioedema or anaphylaxis that was associated with a reaction to a drug
  14. Subjects with the following laboratory values:

    • \< 8.5 g/dL
    • White blood cells \< 3000/mm3
    • \< 100,000/mm3
    • Serum creatinine > 2 times
    • Serum (ALAT) or Aspartate aminotransferase (ASAT) > 2 times upper limit of normal
    • Any other lab values that in the opinion of the investigator might place the subject at unacceptable risk for participation in this study

Open label study phase:

  • Participants must continue to meet inclusion/exclusion criteria as in the short term (double blind) phase of the protocol except subjects who have receiving other than Abatacept
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
524 participants (actual)

Study arms

  • Experimental
    Abatacept (10 mg/Kg) - Open Label

    Drug: Abatacept (BMS-188667)

  • Experimental
    Abatacept (2 mg/kg) - Double blind

    Drug: Abatacept (BMS-188667)

  • Experimental
    Abatacept (10 mg/kg) - Double blind

    Drug: Abatacept (BMS-188667)

  • Experimental
    Placebo - Double blind

    Drug: Placebo

Interventions

  • IV, 10 mg/Kg, monthly, for the duration of the trial

  • Intravenous (IV) infusion, 2 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months

  • Intravenous (IV) infusion, 10 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months

  • DrugPlacebo

    Intravenous (IV) infusion, 0 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months

06

What researchers measure

Primary outcomes

  1. Number of Responders to American College of Rheumatology 20% Improvement Criteria (ACR 20) at Day 180 of the Double-Blind (DB) Period

    ACR 20 response requires a participant to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in Health Assessment Questionnaire score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed for at least 2 consecutive study visits.

    Time frame: Day 180

  2. Participants Receiving Concomitant Disease Modifying Rheumatic Drugs and Biologics in Open-Label (OL) Period

    The number of participants receiving concomitant rheumatoid arthritis treatment with disease modifying rheumatic drugs and/or biologics.

    Time frame: Day 360 to Day 3,060

  3. Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) in OL Period

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with treatment.SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Related AE/SAE=Certain,Probable,Possible,or Missing relationship to drug.

    Time frame: Day 360 to Day 3060

  4. Number of Participants With AEs of Special Interest in OL Period

    AEs were defined as any new untoward medical occurrence or worsening of a pre- existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest were those which may be associated with the use of immunomodulatory agents or infusion of therapeutic proteins. Acute infusional AEs were defined as those that occurred within 1 hour after the start of the infusion. Peri-Infusional AEs were defined as those that occurred within 24 hours after the start of the infusion.

    Time frame: Day 360 to Day 3060

  5. Baseline Serum Immunoglobulin A (IgA) Over Time in OL Period

    Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit and represent only that cohort of participants with measurements available at that post-baseline assessment. Mean Change from Baseline data for these cohorts are presented in Outcome Measure 6.

    Time frame: Baseline (Day 0) and Days 360, 720,1080, 1440, and 1800

  6. Mean Change From Baseline (BL) in IgA Over Time in OL Period

    Blood samples for immunoglobulin assessments were obtained to determine change from baseline in serum IgA. Baseline data for these time-matched cohorts are presented in Outcome Measure 5.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, and 1800

  7. Baseline Immunoglobulin G (IgG) Over Time in OL Period

    Time-matched baseline (Day 0) values and post-baseline vales were presented for each post-baseline visit and represent only that cohort of participants with measurements available at that post-baseline assessment. Mean Change from Baseline data for these cohorts are presented in Outcome Measure 8.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440 and 1800

  8. Mean Change From Baseline (BL) in IgG Over Time in OL Period

    Blood samples for immunoglobulin assessments were obtained to determine change from baseline in serum IgG. Baseline data for these cohorts are presented in Outcome Measure 7.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, and 1800

  9. Baseline Immunoglobulin M (IgM) Over Time in OL Period

    Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit and represent only that cohort of participants with measurements available at that post-baseline assessment. Mean Change from Baseline data for these cohorts are presented in Outcome Measure 10.

    Time frame: Baseline (Day 0) and Days 360, 720,1080,1440, and 1800

  10. Mean Change From Baseline (BL) in IgM in OL Period

    Blood samples for immunoglobulin assessments were obtained to determine change from baseline in serum IgM. Baseline data for these time-matched cohorts are presented in Outcome Measure 9.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, and 1800

  11. Number of Participants With Hematology Values Meeting Marked Abnormality Criteria in OL Period

    Time frame: Day 360 to Day 3060

  12. Number of Participants With Liver and Kidney Function Values Meeting Marked Abnormality Criteria in OL Period

    Time frame: Day 360 to Day 3060

  13. Number of Participants With Electrolyte Values Meeting Marked Abnormality Criteria in OL Period

    Time frame: Day 360 to Day 3060

  14. Number of Participants With Glucose, Protein, Metabolites, and Urinalysis Values Meeting Marked Abnormality Criteria in OL Period

    Time frame: Day 360 to Day 3060

Secondary outcomes

  1. Number of ACR 20 Responders in DB Period

    ACR 20 response requires a participant to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed for at least 2 consecutive study visits.

    Time frame: Days 15, 30, 60, 90, 120, 150,180, 240, 300, and 360

  2. Number of ACR 50 Responders in DB Period

    ACR 50 response requires a participant to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 50 response if the participant had ACR 50 observed for at least 2 consecutive study visits.

    Time frame: Day 15; Day 30; Day 60; Day 90; Day 120; Day 150; Day 180; Day 240; Day 300; Day 360

  3. Number of ACR 70 Responders in DB Period

    ACR 70 response requires a participant to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 70 response if the participant had ACR 70 observed for at least 2 consecutive study visits.

    Time frame: Day 15; Day 30; Day 60; Day 90; Day 120; Day 150; Day 180; Day 240; Day 300; Day 360

  4. ACR Numeric Values (ACR-N)

    The ACR-N is calculated for each participant by taking the lowest percentage improvement in (1) swollen joint count or (2) tender joint count or (3) the median of the remaining 5 components of the ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening.

    Time frame: Day 15; Day 30; Day 60; Day 90; Day 120; Day 150; Day 180; Day 240; Day 300; Day 360

  5. ACR-N Area Under The Curve (AUC) on Day 180 and Day 360

    The AUC for ACR-N is the measure of the area under the curve of the mean change from baseline in ACR-N. The trapezoidal rule was used to compute the AUC. The ACR-N AUC was compared between the two abatacept treatment groups and the placebo group using an analysis of variance (ANOVA) for 6- and 12-month data (Day 180 and Day 360). This allowed for the assessment of subject response throughout the study. See Measure Description in Outcome Measure 18 for a definition of ACR-N.

    Time frame: Baseline and Day 180; Baseline and Day 360

  6. Individual Components of ACR Criteria--Mean Percentage Change From Baseline at Day 180

    Percentage change = 100\*(Baseline value - value at specific visit) / Baseline value. The American College of Rheumatology (ACR) response criteria, based on a core set of variables which includes a tender joint count, a swollen joint count, patient-reported pain scale (Subject Assessment of Physical Function \[SAPF\]), patient and physician global assessments of disease activity (Subject Global Assessment \[SGA\] and Physician Global Assessment \[PGA\]), patient assessment of functional ability, and an acute phase reactant (C-Reactive Protein \[CRP\])

    Time frame: Baseline, Day 180

  7. Individual Components of ACR Criteria--Mean Percentage Change From Baseline at Day 360

    Percentage change = 100\*(Baseline value - value at specific visit) / Baseline value. The American College of Rheumatology (ACR) response criteria, based on a core set of variables which includes a tender joint count, a swollen joint count, patient-reported pain scale (Subject Assessment of Physical Function \[SAPF\]), patient and physician global assessments of disease activity (Subject Global Assessment \[SGA\] and Physician Global Assessment \[PGA\]), patient assessment of functional ability, and an acute phase reactant (C-Reactive Protein \[CRP\])

    Time frame: Baseline, Day 360

  8. Mean Changes From Baseline in the Short Form 36 (SF-36) Physical and Mental Health Component Summary Scores (PCS and MCS) at Day 180 and Day 360

    SF-36 measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS=physical functioning, role-physical, bodily pain, and general health; MCS=vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0=worst score (or quality of life) and 100=best score.

    Time frame: Baseline, Day 180, Day 360

  9. Adjusted Mean Percent Changes From Baseline in the Modified Health Assessment Questionnaire (mHAQ) at Day 180 and Day 360

    A shortened version of the Health Assessment Questionnaire (HAQ), which uses only 8 instead of the 20 original items and is used to assess motor performance in everyday activities, such as dressing, turning a faucet on/off, and getting in and out of a car. Percent change from baseline = (baseline - post baseline value) / baseline value x 100.

    Time frame: Baseline, Day 180, Day 360

  10. Number of Participants With At Least One New Active Joint (Tender Joints and Swollen Joints) at Day 180 and Day 360

    Time frame: Day 180, Day 360

  11. Participants Who Experienced Death, Adverse Events (AEs), Serious AEs (SAEs), and Discontinuations During the Double-Blind Period

    AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded. Related events include those that were considered by the investigator to be certain, probable, or possibly related to study drug.

    Time frame: From the start of study through the end of the double-blind period (at 12 months)

  12. Participants With Laboratory Abnormalities Meeting the Marked Abnormality Criteria for Selected Blood Chemistry Values During Double-Blind Therapy

    Time frame: From the start of study up to 60 days post the end of the 12-month double-blind period

  13. Participants With Laboratory Abnormalities Meeting the Marked Abnormality Criteria for Selected Hematologic Values During Double-Blind Therapy

    Time frame: From the start of study up to 60 days post the end of the 12-month double-blind period

  14. Number of Participants Who Discontinued Due to Lack of Efficacy in the DB and OL Periods

    Time frame: Day 1 to Day 360 (Double-Blind Period), Day 361 to Day 3060 (Open-Label Period)

  15. Immunogenicity Data: Anti-CTLA4Ig Antibodies With Immunoglobulin (IG) Region

    Time frame: Baseline, Days 30, 90, 180, 270, 360

  16. Immunogenicity Data: Anti-CTLA4Ig Antibodies Without IG Region

    Time frame: Baseline, Days 30, 90, 180, 270, 360

  17. Immunogenicity Data: Categories of Post Baseline Value to Baseline Value (VA/PRE) Ratios and Number of Participants With Sero-conversion (Anti-CTLA4Ig Antibodies With IG Region)

    Number of participants with ratio of VA/PRE \<=3, \<3 to \<=9, and \>9. Ratios greater than 9 are incidences of Anti-CTLA4Ig sero-conversion.

    Time frame: Baseline, Days 30, 90, 180, 270, 360

  18. Immunogenicity Data: Categories of Post Baseline Value to Baseline Value (VA/PRE) Ratios and Number of Participants With Sero-conversion(Anti-CTLA4Ig Antibodies Without IG Region)

    Number of participants with ratio of VA/PRE \<=3, \<3 to \<=9, and \>9. Ratios greater than 9 are incidences of Anti-CTLA4Ig sero-conversion.

    Time frame: Baseline, Days 30, 90, 180, 270, 360

  19. Pharmacodynamic Measure: Mean Changes From Baseline in Rheumatoid Factor at Day 180 and Day 360

    Time frame: Baseline, Day 180, Day 360

  20. Pharmacodynamic Measure: Mean Changes From Baseline in Interleukin-6 at Day 180 and Day 360

    Time frame: Baseline, Day 180, Day 360

  21. Pharmacodynamic Measure: Mean Changes From Baseline in Plasma Soluble Interleukin-2 Receptor (sIL-2R) at Day 180 and Day 360

    Time frame: Baseline, Day 180, Day 360

  22. Pharmacodynamic Measure: Mean Changes From Baseline in E-Selectin at Day 180 and Day 360

    Time frame: Baseline, Day 180, Day 360

  23. Pharmacodynamic Measure: Mean Changes From Baseline in Soluble Inter-Cellular Adhesion Molecule 1 (sICAM-1) at Day 180 and Day 360

    Time frame: Baseline, Day 180, Day 360

  24. Pharmacodynamic Measure: Mean Changes From Baseline in Tumor Necrosis Factor (TNF)-Alpha at Day 180 and Day 360

    Time frame: Baseline, Day 180, Day 360

  25. Number of ACR 20 Responders in OL Period

    ACR 20 response requires a participant to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in Health Assessment Questionnaire score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed for at least 2 consecutive study visits.

    Time frame: Days 360, 450, 540, 630, 720, 810, 900, 1080, 1350, 1440, 1530, 1620, 1710, 1800, 1980, 2160, 2340, 2520, 2700, 2880, and 3060

  26. Number of ACR 50 Responders in the OL Period

    ACR 50 response requires a participant to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 50 response if the participant had ACR 50 observed for at least 2 consecutive study visits.

    Time frame: Days 360, 450, 540, 630, 720, 810, 900, 1080, 1350, 1440, 1530, 1620, 1710, 1800, 1980, 2160, 2340, 2520, 2700, 2880, and 3060

  27. Number of ACR 70 Responders in the OL Period

    ACR 70 response requires a participant to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in 3 of the following 5 parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 70 response if the participant had ACR 70 observed for at least 2 consecutive study visits.

    Time frame: Days 360, 450, 540, 630, 720, 810, 900, 1080, 1350, 1440, 1530, 1620, 1710, 1800, 1980, 2160, 2340, 2520, 2700, 2880, and 3060

  28. Number of Participants With a Clinically Meaningful Improvement on the Modified Health Assessment Questionnaire (mHAQ) in OL Period

    The mHAQ is a self-administered questionnaire composed of 20 questions that assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The answers are graded on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The HAQ disease index is a weighted sum of the scale scores, with a higher score indicating poorer function. A clinically meaningful improvement was defined as a reduction from baseline in mHAQ score of at least 0.30 units.

    Time frame: Days 360, 720,1080, 1440, 1800, 2160, 2520, 2880, and 3060

  29. Baseline Level of Serum Rheumatoid Factor Over Time in OL Period

    Serum evaluations were carried out to determine participant baseline rheumatoid factor serum concentration. Time-matched baseline(Day 0) values and post-baseline vales were presented for each post-baseline visit and represent only that cohort of participants with measurements available at that post-baseline assessment.

    Time frame: Baseline (Day 0) and Days 360, 720,1080, 1440, 1800, 2160, 2520, 2880, and 3060

  30. Mean Change From Baseline in Serum Rheumatoid Factor Level Over Time in OL Period

    Serum evaluations were carried out to determine participant change from baseline in rheumatoid factor serum concentration. Mean change from baseline = value at post-baseline OL time point-value and baseline OL time point.

    Time frame: Baseline (Day 0) and Days 360, 720,1080, 1440, 1800, 2160, 2520, 2880, and 3060

  31. Mean Baseline Soluble Serum Interleukin-2 Receptor Level (sIL2-r) Over Time in OL Period

    Serum evaluations were carried out to determine participant serum levels of sIL2-r at baseline. Time-matched baseline (Day 0) values and post-baseline vales were presented for each post-baseline visit and represent only that cohort of participants with measurements available at that post-baseline assessment.

    Time frame: Baseline (Day 0) and Days 360, 720,1080, 1440, 1800, 2160, 2520, 2880, and 3060

  32. Mean Change From Baseline in sIL2-r Over Time in OL Period

    Serum evaluations were carried out to determine participant serum levels of sIL2-r. Mean change from baseline=value at post-baseline OL time point-value and baseline OL time point.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, and 1800

  33. Mean Baseline Serum C-Reactive Protein Level Over Time in OL Period

    Serum evaluations were carried out to evaluate participant serum CRP concentrations at baseline. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080,1440,1800, 2160, 2520, 2880, 3060

  34. Mean Change From Baseline in Level of C Reactive Protein Over Time in OL Period

    Serum evaluations were carried out to evaluate participant concentrations of serum C reactive protein. Mean change from baseline=value at post-baseline OL time point-value and baseline OL time point.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, 3060

  35. Mean Baseline Physical Component Summary (PCS) of the Short-Form 36 (SF-36) Over Time in OL Period

    SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 50.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2880, and 3060

  36. Mean Change From Baseline (BL) in the Physical Component Summary (PCS) of the SF-36 Over Time in OL Period

    The SF-36 consists of 2 summaries, the PCS and the MCS, and 8 individual indexes. The MCS addresses 4 of the 8 individual indices: vitality, social functioning, role-emotional, and mental health. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from baseline=value at post-baseline OL time point-value and baseline OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 49.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2880, and 3060

  37. Mean Baseline Mental Component Summary (MCS) of the SF-36 Over Time in OL Period

    SF-36=PCS, MCS, \& 8 individual indices. MCS addresses 4 of the 8 indices: vitality, social functioning, role-emotional, \& mental health. Subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched baseline (Day 0) values \& post-baseline (BL) values are presented for each post-BL visit \& represent only that cohort with measurements available at that post-BL assessment. See Outcome Measure 51 for Change from BL.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2880, and 3060

  38. Mean Change From Baseline (BL) in the MCS of the SF-36 Over Time in OL Period

    The SF-36 consists of 2 summaries, the PCS and the MCS, and 8 individual indexes. The MCS addresses 4 of the 8 individual indices: vitality, social functioning, role-emotional, and mental health. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from baseline=value at post-baseline OL time point-value and baseline OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 51.

    Time frame: Baseline (Day 0) and Days 360, 450, 540, 630, 720, 810, 900, 1080, 1350, 1440, 1530, 1620, 1710, 1800, 1980, 2160, 2340, 2520, 2700, 2880, and 3060

  39. Mean Baseline (BL) Physical Functioning Domain of the SF-36 Over Time in OL Period

    SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 54.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060

  40. Mean Change From Baseline (BL) in the Physical Functioning Domain of the SF-36 Over Time in OL Period

    SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 53.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060

  41. Mean Baseline Role-Physical Domain of the SF-36 Over Time in OL Period

    SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 56.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060

  42. Mean Change From Baseline (BL) in the Role-Physical Domain of the SF-36 Over Time in OL Period

    SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 55.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060

  43. Mean Baseline Bodily Pain Domain of the SF-36 Over Time in OL Period

    SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 58.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060

  44. Mean Change From BL in the Bodily Pain Domain of the SF-36 Over Time in OL Period

    SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 57.

    Time frame: BL (Day 0); Day 360; Day 720; Day 1,080; Day 1,440; Day 1,800; Day 2,160; Day 2,520; Day 2,880; Day 3,060

  45. Mean BL General Health Domain of the SF-36 Over Time in OL Period

    SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 60.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060

  46. Mean Change From Baseline (BL) in the General Health Domain of the SF-36 Over Time in OL Period

    SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 59.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060

  47. Mean Baseline Vitality Domain of the SF-36 Over Time in OL Period

    SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 62.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060

  48. Mean Change From Baseline (BL) in the Vitality Domain of the SF-36 Over Time in OL Period

    SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 61.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060

  49. Mean Baseline Social Functioning Domain of the SF-36 Over Time in OL Period

    SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 64.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060

  50. Mean Change From Baseline (BL) in the Social Functioning Domain of the SF-36 Over Time in OL Period

    SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 63.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060

  51. Mean Baseline Role-Emotional Domain of the SF-36 Over Time in OL Period

    SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 66.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060

  52. Mean Change From Baseline (BL) in the Role-Emotional Domain of the SF-36 Over Time in OL Period

    SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 65.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060

  53. Mean Baseline Mental Health Domain of the SF-36 Over Time in OL Period

    SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 68.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060

  54. Mean Change From Baseline (BL) in the Mental Health Domain of the SF-36 Over Time in OL Period

    SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 67.

    Time frame: Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060

07

Results

Posted Jun 1, 2012

Participant flow

Double-Blind Period
Participant flow — Double-Blind Period
MilestoneDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + MethotrexateOpen-Label (OL) Abatacept (10 mg / kg)
Started1151051190
Completed day 1 to day 1819880780
Completed9074710
Not completed2531480
Withdrew: Adverse event59110
Withdrew: Death0100
Withdrew: Lost to follow-up1200
Withdrew: Other reason1010
Withdrew: Lack of efficacy1317300
Withdrew: Withdrawal by subject5260
Open-Label Period
Participant flow — Open-Label Period
MilestoneDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + MethotrexateOpen-Label (OL) Abatacept (10 mg / kg)
Started000219
Completed00082
Not completed000137
Withdrew: Death0007
Withdrew: Adverse event00046
Withdrew: Lack of efficacy00026
Withdrew: Lost to follow-up0003
Withdrew: Withdrawal by subject00031
Withdrew: Administrative reason by sponsor0009
Withdrew: Other reasons00015

Outcome measures

PrimaryNumber of Responders to American College of Rheumatology 20% Improvement Criteria (ACR 20) at Day 180 of the Double-Blind (DB) Period

ACR 20 response requires a participant to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in Health Assessment Questionnaire score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed for at least 2 consecutive study visits.

Time frame:
Day 180
Reported as:
Number · Participants
Number of Responders to American College of Rheumatology 20% Improvement Criteria (ACR 20) at Day 180 of the Double-Blind (DB) Period
ParticipantsDB Abatacept 10 mg/kg + MethotrexateDB Abatacept 2 mg/kg + MethotrexateDB Placebo + Methotrexate
Number of Responders to American College of Rheumatology 20% Improvement Criteria (ACR 20) at Day 180 of the Double-Blind (DB) Period704442
Statistical analysis
  • DB Abatacept 10 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = <0.001 · Point estimate of difference: 25.6 · 95% CI 12.8 to 38.4
  • DB Abatacept 2 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = 0.31 · Point estimate of difference: 6.6 · 95% CI -6.2 to 19.4
SecondaryNumber of ACR 20 Responders in DB Period

ACR 20 response requires a participant to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed for at least 2 consecutive study visits.

Time frame:
Days 15, 30, 60, 90, 120, 150,180, 240, 300, and 360
Reported as:
Number · Participants
Number of ACR 20 Responders in DB Period
ParticipantsDB Abatacept 10 mg/kg + MethotrexateDB Abatacept 2 mg/kg + MethotrexateDB Placebo + Methotrexate
Day 1530924
Day 30482236
Day 60653541
Day 90624042
Day 120714745
Day 150674642
Day 180704442
Day 240724342
Day 300734141
Day 360724443
Statistical analysis
  • DB Abatacept 10 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = 0.283 · Point estimate of difference: 5.9 · 95% CI -4.9 to 16.7
  • DB Abatacept 2 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = 0.015 · Point estimate of difference: -11.6 · 95% CI -20.9 to -2.3
  • DB Abatacept 10 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = 0.067 · Point estimate of difference: 11.5 · 95% CI -0.8 to 23.8
  • DB Abatacept 2 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = 0.113 · Point estimate of difference: -9.3 · 95% CI -20.8 to 2.2
  • DB Abatacept 10 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = <0.001 · Point estimate of difference: 22.1 · 95% CI 9.3 to 34.8
  • DB Abatacept 2 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = 0.86 · Point estimate of difference: -1.1 · 95% CI -13.5 to 11.3
  • DB Abatacept 10 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = 0.004 · Point estimate of difference: 18.6 · 95% CI 5.9 to 31.4
  • DB Abatacept 2 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = 0.664 · Point estimate of difference: 2.8 · 95% CI -9.8 to 15.4
  • DB Abatacept 10 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = <0.001 · Point estimate of difference: 23.9 · 95% CI 11.1 to 36.7
  • DB Abatacept 2 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = 0.292 · Point estimate of difference: 6.9 · 95% CI -6.0 to 19.9
  • DB Abatacept 10 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = <0.001 · Point estimate of difference: 23.0 · 95% CI 10.2 to 35.8
  • DB Abatacept 2 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = 0.193 · Point estimate of difference: 8.5 · 95% CI -4.3 to 21.3
  • DB Abatacept 10 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = <0.001 · Point estimate of difference: 25.6 · 95% CI 12.8 to 38.4
  • DB Abatacept 2 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = 0.31 · Point estimate of difference: 6.6 · 95% CI -6.2 to 19.4
  • DB Abatacept 10 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = <0.001 · Point estimate of difference: 27.3 · 95% CI 14.5 to 40.1
  • DB Abatacept 2 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = 0.384 · Point estimate of difference: 5.7 · 95% CI -7.1 to 18.4
  • DB Abatacept 10 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = <0.001 · Point estimate of difference: 29.0 · 95% CI 16.2 to 41.8
  • DB Abatacept 2 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = 0.476 · Point estimate of difference: 4.6 · 95% CI -8.0 to 17.2
  • DB Abatacept 10 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = <0.001 · Point estimate of difference: 26.5 · 95% CI 13.7 to 39.3
  • DB Abatacept 2 mg/kg + Methotrexate vs DB Placebo + Methotrexate · Chi-squared · p = 0.377 · Point estimate of difference: 5.8 · 95% CI -7.0 to 18.6
SecondaryNumber of ACR 50 Responders in DB Period

ACR 50 response requires a participant to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 50 response if the participant had ACR 50 observed for at least 2 consecutive study visits.

Time frame:
Day 15; Day 30; Day 60; Day 90; Day 120; Day 150; Day 180; Day 240; Day 300; Day 360
Reported as:
Number · Participants
Number of ACR 50 Responders in DB Period
ParticipantsDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + Methotrexate
Day 15203
Day 301647
Day 60251418
Day 90281815
Day 120381818
Day 150421819
Day 180422414
Day 240412224
Day 300452318
Day 360482424
Statistical analysis
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.679 · Point estimate of difference: -0.8 · 95% CI -4.5 to 2.9
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.101 · Point estimate of difference: -2.5 · 95% CI -5.5 to 0.5
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.039 · Point estimate of difference: 8.0 · 95% CI 0.4 to 15.7
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.474 · Point estimate of difference: -2.1 · 95% CI -7.7 to 3.6
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.192 · Point estimate of difference: 6.6 · 95% CI -3.3 to 16.5
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.702 · Point estimate of difference: -1.8 · 95% CI -11.0 to 7.4
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.02 · Point estimate of difference: 11.7 · 95% CI 1.8 to 21.7
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.339 · Point estimate of difference: 4.5 · 95% CI -4.8 to 13.8
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.001 · Point estimate of difference: 17.9 · 95% CI 7.0 to 28.9
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.682 · Point estimate of difference: 2.0 · 95% CI -7.6 to 11.7
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = <0.001 · Point estimate of difference: 20.6 · 95% CI 9.3 to 31.8
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.813 · Point estimate of difference: 1.2 · 95% CI -8.6 to 10.9
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = <0.001 · Point estimate of difference: 24.8 · 95% CI 13.8 to 35.7
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.027 · Point estimate of difference: 11.1 · 95% CI 1.2 to 20.9
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.008 · Point estimate of difference: 15.5 · 95% CI 4.0 to 27.0
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.885 · Point estimate of difference: 0.8 · 95% CI -9.8 to 11.4
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = <0.001 · Point estimate of difference: 24.0 · 95% CI 12.6 to 35.4
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.19 · Point estimate of difference: 6.8 · 95% CI -3.4 to 16.9
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = <0.001 · Point estimate of difference: 21.6 · 95% CI 9.7 to 33.4
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.625 · Point estimate of difference: 2.7 · 95% CI -8.1 to 13.5
SecondaryNumber of ACR 70 Responders in DB Period

ACR 70 response requires a participant to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 70 response if the participant had ACR 70 observed for at least 2 consecutive study visits.

Time frame:
Day 15; Day 30; Day 60; Day 90; Day 120; Day 150; Day 180; Day 240; Day 300; Day 360
Reported as:
Number · Participants
Number of ACR 70 Responders in DB Period
ParticipantsDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + Methotrexate
Day 15000
Day 30430
Day 601040
Day 901051
Day 1201564
Day 1501664
Day 18019112
Day 2402196
Day 30027113
Day 36024139
Statistical analysis
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.04 · Point estimate of difference: 3.5 · 95% CI 0.2 to 6.8
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.063 · Point estimate of difference: 2.9 · 95% CI -0.2 to 5.9
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.001 · Point estimate of difference: 8.7 · 95% CI 3.5 to 13.9
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.032 · Point estimate of difference: 3.8 · 95% CI 0.3 to 7.3
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.005 · Point estimate of difference: 7.9 · 95% CI 2.4 to 13.3
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.07 · Point estimate of difference: 3.9 · 95% CI -0.3 to 8.2
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.007 · Point estimate of difference: 9.7 · 95% CI 2.7 to 16.7
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.395 · Point estimate of difference: 2.4 · 95% CI -3.1 to 7.8
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.004 · Point estimate of difference: 10.6 · 95% CI 3.4 to 17.7
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.395 · Point estimate of difference: 2.4 · 95% CI -3.1 to 7.8
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = <0.001 · Point estimate of difference: 14.8 · 95% CI 7.5 to 22.2
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.005 · Point estimate of difference: 8.8 · 95% CI 2.7 to 14.9
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.002 · Point estimate of difference: 13.2 · 95% CI 5.0 to 21.4
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.292 · Point estimate of difference: 3.5 · 95% CI -3.0 to 10.1
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = <0.001 · Point estimate of difference: 21.0 · 95% CI 12.4 to 29.5
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.014 · Point estimate of difference: 8.0 · 95% CI 1.6 to 14.3
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.003 · Point estimate of difference: 13.3 · 95% CI 4.4 to 22.2
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · Chi-squared · p = 0.227 · Point estimate of difference: 4.8 · 95% CI -3.0 to 12.6
SecondaryACR Numeric Values (ACR-N)

The ACR-N is calculated for each participant by taking the lowest percentage improvement in (1) swollen joint count or (2) tender joint count or (3) the median of the remaining 5 components of the ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening.

Time frame:
Day 15; Day 30; Day 60; Day 90; Day 120; Day 150; Day 180; Day 240; Day 300; Day 360
Reported as:
Mean · units on a scale
ACR Numeric Values (ACR-N)
units on a scaleDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + Methotrexate
Day 15 (n=113, 104, 118)11.09 ± 15.535.26 ± 10.379.07 ± 14.76
Day 30 (n=115, 104, 117)20.45 ± 23.4112.06 ± 18.1113.20 ± 17.85
Day 60 (n=114, 105, 119)28.85 ± 26.7817.69 ± 22.8317.09 ± 20.90
Day 90 (n=115, 105, 118)29.03 ± 27.3821.12 ± 26.1016.93 ± 21.61
Day 120 (n=114, 105, 115)33.80 ± 29.3522.87 ± 26.1019.26 ± 23.70
Day 150 (n=114, 103, 118)36.34 ± 30.2922.69 ± 24.1519.37 ± 24.74
Day 180 (n=114, 104, 118)37.65 ± 30.3924.67 ± 29.0317.29 ± 22.02
Day 240 (n=115, 104, 119)38.34 ± 31.4923.49 ± 27.5120.71 ± 25.97
Day 300 (n=114, 105, 119)39.69 ± 31.0821.82 ± 27.9918.69 ± 23.53
Day 360 (n=115, 105, 119)40.87 ± 31.6924.55 ± 29.3720.49 ± 26.14
Statistical analysis
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.2676 · Mean difference (final values): 2.02 · 95% CI -1.56 to 5.61Estimate= Model AUC for abatacept+methotrexate - Model AUC for placebo+methotrexate
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.0418 · Mean difference (final values): -3.80 · 95% CI -7.46 to -0.14Estimate= Model AUC for abatacept+methotrexate - Model AUC for placebo+methotrexate
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.0061 · Mean difference (final values): 7.25 · 95% CI 2.08 to 12.41Estimate= Model AUC for abatacept+methotrexate - Model AUC for placebo+methotrexate
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.6713 (ANOVA model: AUC = treatment) · Mean difference (final values): -1.14 · 95% CI -6.45 to 4.16Estimate= Model AUC for abatacept+methotrexate - Model AUC for placebo+methotrexate
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.0002 · Mean difference (final values): 11.75 · 95% CI 5.67 to 17.84Estimate= Model AUC for abatacept+methotrexate - Model AUC for placebo+methotrexate
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.8495 · Mean difference (final values): 0.60 · 95% CI -5.62 to 6.82Estimate= Model AUC for abatacept+methotrexate - Model AUC for placebo+methotrexate
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.0003 · Mean difference (final values): 12.10 · 95% CI 5.63 to 18.56Estimate= Model AUC for abatacept+methotrexate - Model AUC for placebo+methotrexate
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.0003 · Mean difference (final values): 4.19 · 95% CI -2.44 to 10.81Estimate= Model AUC for abatacept+methotrexate - Model AUC for placebo+methotrexate
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.0001 · Mean difference (final values): 14.54 · 95% CI 7.28 to 21.81Estimate= Model AUC for abatacept+methotrexate - Model AUC for placebo+methotrexate
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.3141 · Mean difference (final values): 3.60 · 95% CI -3.43 to 10.64Estimate= Model AUC for abatacept+methotrexate - Model AUC for placebo+methotrexate
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.0001 · Mean difference (final values): 16.96 · 95% CI 8.49 to 25.43Estimate= Model AUC for abatacept+methotrexate - Model AUC for placebo+methotrexate
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.3552 · Mean difference (final values): 3.32 · 95% CI -3.73 to 10.37Estimate= Model AUC for abatacept+methotrexate - Model AUC for placebo+methotrexate
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.0001 · Mean difference (final values): 20.36 · 95% CI 10.19 to 30.54Estimate= Model AUC for abatacept+methotrexate - Model AUC for placebo+methotrexate
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.0451 · Mean difference (final values): 7.38 · 95% CI 0.16 to 14.60Estimate= Model AUC for abatacept+methotrexate - Model AUC for placebo+methotrexate
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.0001 · Mean difference (final values): 17.63 · 95% CI 8.83 to 26.44Estimate= Model AUC for abatacept+methotrexate - Model AUC for placebo+methotrexate
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.4669 · Mean difference (final values): 2.78 · 95% CI -4.73 to 10.28Estimate= Model AUC for abatacept+methotrexate - Model AUC for placebo+methotrexate
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.0001 · Mean difference (final values): 21.00 · 95% CI 10.51 to 31.48Estimate= Model AUC for abatacept+methotrexate - Model AUC for placebo+methotrexate
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 3.13 · Mean difference (final values): 3.13 · 95% CI -4.15 to 10.41Estimate= Model AUC for abatacept+methotrexate - Model AUC for placebo+methotrexate
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.0001 · Mean difference (final values): 20.38 · 95% CI 10.20 to 30.56Estimate= Model AUC for abatacept+methotrexate - Model AUC for placebo+methotrexate
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.2989 · Mean difference (final values): 4.06 · 95% CI -3.61 to 11.72Estimate= Model AUC for abatacept+methotrexate - Model AUC for placebo+methotrexate
SecondaryACR-N Area Under The Curve (AUC) on Day 180 and Day 360

The AUC for ACR-N is the measure of the area under the curve of the mean change from baseline in ACR-N. The trapezoidal rule was used to compute the AUC. The ACR-N AUC was compared between the two abatacept treatment groups and the placebo group using an analysis of variance (ANOVA) for 6- and 12-month data (Day 180 and Day 360). This allowed for the assessment of subject response throughout the study. See Measure Description in Outcome Measure 18 for a definition of ACR-N.

Time frame:
Baseline and Day 180; Baseline and Day 360
Reported as:
Mean · percentage*days
ACR-N Area Under The Curve (AUC) on Day 180 and Day 360
percentage*daysDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + Methotrexate
Day 1805021.70 ± 317.93242.54 ± 332.72889.07 ± 312.5
Day 36012035.1 ± 711.77447.87 ± 744.86393.49 ± 699.6
Statistical analysis
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.0001 (ANOVA model: AUC = treatment) · Mean difference (final values): 2132.63 · 95% CI 1067.32 to 3197.94Estimate = Model AUC for Aripiprazole+MTX - Model AUC for PLACEBO+MTX
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.4393 (ANOVA model: AUC = treatment) · Mean difference (final values): 353.47 · 95% CI -544.46 to 1251.41Estimate = Model AUC for Aripiprazole+MTX - Model AUC for PLACEBO+MTX
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.0001 (ANOVA model: AUC = treatment) · Mean difference (final values): 5641.60 · 95% CI 2823.46 to 8459.74Estimate = Model AUC for Aripiprazole+MTX - Model AUC for PLACEBO+MTX
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · ANOVA · p = 0.3029 (ANOVA model: AUC = treatment) · Mean difference (final values): 1054.38 · 95% CI -955.59 to 3064.35Estimate = Model AUC for Aripiprazole+MTX - Model AUC for PLACEBO+MTX
SecondaryIndividual Components of ACR Criteria--Mean Percentage Change From Baseline at Day 180

Percentage change = 100\*(Baseline value - value at specific visit) / Baseline value. The American College of Rheumatology (ACR) response criteria, based on a core set of variables which includes a tender joint count, a swollen joint count, patient-reported pain scale (Subject Assessment of Physical Function \[SAPF\]), patient and physician global assessments of disease activity (Subject Global Assessment \[SGA\] and Physician Global Assessment \[PGA\]), patient assessment of functional ability, and an acute phase reactant (C-Reactive Protein \[CRP\])

Time frame:
Baseline, Day 180
Reported as:
Mean · percentage change
Individual Components of ACR Criteria--Mean Percentage Change From Baseline at Day 180
percentage changeDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + Methotrexate
Tender Joints (n=114, 104, 118)59.8 ± 3.643.2 ± 4.131.9 ± 5.0
Swollen Joints (n=114, 104, 118)55.3 ± 3.545.3 ± 4.133.5 ± 4.3
Pain (n=109, 102, 118)46.2 ± 4.122.1 ± 5.88.2 ± 7.0
SAPF (n=107, 98, 110)41.2 ± 4.621.6 ± 6.513.7 ± 5.5
Subject Global Assessment (n=111, 103, 118)40.8 ± 4.79.1 ± 10.417.5 ± 4.1
Physician Global Assessment (n=111, 103, 116)51.9 ± 3.438.7 ± 4.425.1 ± 3.5
C-Reactive Protein (n=108, 98, 114)31.8 ± 6.316.4 ± 7.0-23.4 ± 11.0
SecondaryIndividual Components of ACR Criteria--Mean Percentage Change From Baseline at Day 360

Percentage change = 100\*(Baseline value - value at specific visit) / Baseline value. The American College of Rheumatology (ACR) response criteria, based on a core set of variables which includes a tender joint count, a swollen joint count, patient-reported pain scale (Subject Assessment of Physical Function \[SAPF\]), patient and physician global assessments of disease activity (Subject Global Assessment \[SGA\] and Physician Global Assessment \[PGA\]), patient assessment of functional ability, and an acute phase reactant (C-Reactive Protein \[CRP\])

Time frame:
Baseline, Day 360
Reported as:
Mean · percentage change
Individual Components of ACR Criteria--Mean Percentage Change From Baseline at Day 360
percentage changeDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + Methotrexate
Tender Joints (n=114, 104, 118)66.4 ± 3.843.6 ± 4.330.0 ± 5.3
Swollen Joints (n=114, 104, 118)59.7 ± 3.746.4 ± 4.536.2 ± 4.4
Pain (n=109, 102, 118)44.9 ± 4.726.2 ± 5.965.2 ± 12.6
SAPF (n=107, 98, 110)42.3 ± 4.322.9 ± 5.010.3 ± 5.9
Subject Global Assessment (n=111, 103, 118)41.0 ± 5.116.0 ± 8.92.0 ± 19.1
Physician Global Assessment (n=111, 103, 116)53.5 ± 3.437.9 ± 4.224.1 ± 3.8
C-Reactive Protein (n=108, 98, 114)27.6 ± 9.911.0 ± 9.5-31.3 ± 12.6
SecondaryMean Changes From Baseline in the Short Form 36 (SF-36) Physical and Mental Health Component Summary Scores (PCS and MCS) at Day 180 and Day 360

SF-36 measures health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores: PCS=physical functioning, role-physical, bodily pain, and general health; MCS=vitality, social functioning, role-emotional, and mental health. Scoring is done for both subscores and summary scores. For both, 0=worst score (or quality of life) and 100=best score.

Time frame:
Baseline, Day 180, Day 360
Reported as:
Mean · units on a scale
Mean Changes From Baseline in the Short Form 36 (SF-36) Physical and Mental Health Component Summary Scores (PCS and MCS) at Day 180 and Day 360
units on a scaleDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + Methotrexate
PCS, Mean Change at Day 180 (n=115, 104, 119)8.3 ± 0.94.6 ± 0.73.0 ± 0.6
MCS, Mean Change at Day 180 (n=115, 104, 119)5.0 ± 1.02.7 ± 1.23.2 ± 1.0
PCS, Mean Change at Day 360 (n=115, 104, 119)8.1 ± 0.95.3 ± 0.82.8 ± 0.7
PCS, Mean Change at Day 360 (n=115, 104, 119)5.7 ± 1.03.5 ± 1.13.0 ± 0.9
SecondaryAdjusted Mean Percent Changes From Baseline in the Modified Health Assessment Questionnaire (mHAQ) at Day 180 and Day 360

A shortened version of the Health Assessment Questionnaire (HAQ), which uses only 8 instead of the 20 original items and is used to assess motor performance in everyday activities, such as dressing, turning a faucet on/off, and getting in and out of a car. Percent change from baseline = (baseline - post baseline value) / baseline value x 100.

Time frame:
Baseline, Day 180, Day 360
Reported as:
Mean · Percentage of Change on mHAQ scale
Adjusted Mean Percent Changes From Baseline in the Modified Health Assessment Questionnaire (mHAQ) at Day 180 and Day 360
Percentage of Change on mHAQ scaleDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + Methotrexate
Mean Percentage Change at Day 180 (n=107, 98, 110)41.39 ± 5.4321.41 ± 5.6713.73 ± 5.35
Mean PercentageChange at Day 360 (n=109, 100, 111)42.49 ± 5.0522.74 ± 5.2710.26 ± 5.00
Statistical analysis
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · ANCOVA · p = 0.0003 · Mean difference (final values): 27.66 · 95% CI 12.67 to 42.66Estimate = adjusted % change (BMS10mg/kg+MTX or BMS 2mg/kg+MTX) - adjusted change for placebo+MTX
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · ANCOVA · p = 0.3253 · Mean difference (final values): 7.68Estimate = adjusted % change (BMS10mg/kg+MTX or BMS 2mg/kg+MTX) - adjusted change for placebo+MTX
  • Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX) vs Double-Blind (DB) Placebo + Methotrexate · ANCOVA · p = 0.0001 · Mean difference (final values): 32.24 · 95% CI 16.14 to 48.33Estimate = adjusted % change (BMS10mg/kg+MTX or BMS 2mg/kg+MTX) - adjusted change for placebo+MTX
  • Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate vs Double-Blind (DB) Placebo + Methotrexate · ANCOVA · p = 0.0869 · Mean difference (final values): 12.48 · 95% CI -1.82 to 26.78Estimate = adjusted % change (BMS10mg/kg+MTX or BMS 2mg/kg+MTX) - adjusted change for placebo+MTX
SecondaryNumber of Participants With At Least One New Active Joint (Tender Joints and Swollen Joints) at Day 180 and Day 360
Time frame:
Day 180, Day 360
Reported as:
Number · participants
Number of Participants With At Least One New Active Joint (Tender Joints and Swollen Joints) at Day 180 and Day 360
participantsDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + Methotrexate
New Tender Joints(s) at Day 180476570
New Swollen Joints(s) at Day 180555975
New Tender Joints(s) at Day 360336269
New Swollen Joints(s) at Day 360455969
SecondaryParticipants Who Experienced Death, Adverse Events (AEs), Serious AEs (SAEs), and Discontinuations During the Double-Blind Period

AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded. Related events include those that were considered by the investigator to be certain, probable, or possibly related to study drug.

Time frame:
From the start of study through the end of the double-blind period (at 12 months)
Reported as:
Number · Participants
Participants Who Experienced Death, Adverse Events (AEs), Serious AEs (SAEs), and Discontinuations During the Double-Blind Period
ParticipantsDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + Methotrexate
Deaths010
SAEs141919
Discontinuations due to SAEs363
Related SAEs252
Discontinuations due to AEs61011
AEs104104112
Related AEs565058
SecondaryParticipants With Laboratory Abnormalities Meeting the Marked Abnormality Criteria for Selected Blood Chemistry Values During Double-Blind Therapy
Time frame:
From the start of study up to 60 days post the end of the 12-month double-blind period
Reported as:
Number · Participants
Participants With Laboratory Abnormalities Meeting the Marked Abnormality Criteria for Selected Blood Chemistry Values During Double-Blind Therapy
ParticipantsDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + Methotrexate
High Alanine Aminotransferase (ALT)012
High Aspartate Aminotransferase (AST)010
High Creatinine434
Low Potassium231
High Potassium134
PrimaryParticipants Receiving Concomitant Disease Modifying Rheumatic Drugs and Biologics in Open-Label (OL) Period

The number of participants receiving concomitant rheumatoid arthritis treatment with disease modifying rheumatic drugs and/or biologics.

Time frame:
Day 360 to Day 3,060
Reported as:
Number · Participants
Participants Receiving Concomitant Disease Modifying Rheumatic Drugs and Biologics in Open-Label (OL) Period
ParticipantsOL Abatacept: Original 10 mg / kg GroupOL Abatacept: Original 2 mg / kg GroupOL Abatacept: Original Placebo Group
Methotrexate846867
Corticosteroids (oral and/or injectable)725756
Nonsteroidal antiinfllammatory drugs786364
Azanthioprine101
Chloroquine011
Cyclosporine210
Gold Sodium Thiomalate010
Hydroxychloroquine232
Leflunamide201
Sulfasalazine001
Adalimumab010
Etanercept010
Infliximab210
PrimaryNumber of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) in OL Period

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with treatment.SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Related AE/SAE=Certain,Probable,Possible,or Missing relationship to drug.

Time frame:
Day 360 to Day 3060
Reported as:
Number · Participants
Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) in OL Period
ParticipantsOL Abatacept (10 mg / kg)
AEs211
Related AEs144
Discontinued Due to AEs44
SAEs117
Related SAEs37
Discontinued Due to SAEs33
Deaths8
PrimaryNumber of Participants With AEs of Special Interest in OL Period

AEs were defined as any new untoward medical occurrence or worsening of a pre- existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest were those which may be associated with the use of immunomodulatory agents or infusion of therapeutic proteins. Acute infusional AEs were defined as those that occurred within 1 hour after the start of the infusion. Peri-Infusional AEs were defined as those that occurred within 24 hours after the start of the infusion.

Time frame:
Day 360 to Day 3060
Reported as:
Number · Participants
Number of Participants With AEs of Special Interest in OL Period
ParticipantsOL Abatacept (10 mg / kg)
Infections/Infestations179
Malignant Neoplasms20
Autoimmune Disorders20
Acute Infusional AEs20
Peri-Infusional AEs47
PrimaryBaseline Serum Immunoglobulin A (IgA) Over Time in OL Period

Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit and represent only that cohort of participants with measurements available at that post-baseline assessment. Mean Change from Baseline data for these cohorts are presented in Outcome Measure 6.

Time frame:
Baseline (Day 0) and Days 360, 720,1080, 1440, and 1800
Reported as:
Mean · mg/dL
Baseline Serum Immunoglobulin A (IgA) Over Time in OL Period
mg/dLOL Abatacept: Original 10 mg / kg GroupOL Abatacept: Original 2 mg / kg GroupOL Abatacept: Original Placebo Group
Baseline for Day 360 cohort (n=74, 59, 60)308.09 ± 152.27341.54 ± 148.48264.22 ± 133.90
Baseline for Day 720 cohort (n=71, 53, 53)290.25 ± 146.27338.58 ± 151.76256.64 ± 132.78
Baseline for Day 1080 cohort (n=59, 45, 45)287.27 ± 140.22321.02 ± 153.81266.89 ± 143.48
Baseline for Day 1440 cohort (n=54, 37, 37)287.09 ± 136.50327.27 ± 162.13250.11 ± 127.88
Baseline for Day 1800 cohort (n=50, 38, 34)292.78 ± 146.91327.34 ± 163.27244.71 ± 118.03
PrimaryMean Change From Baseline (BL) in IgA Over Time in OL Period

Blood samples for immunoglobulin assessments were obtained to determine change from baseline in serum IgA. Baseline data for these time-matched cohorts are presented in Outcome Measure 5.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, and 1800
Reported as:
Mean · mg/dL
Mean Change From Baseline (BL) in IgA Over Time in OL Period
mg/dLOL Abatacept: Original 10 mg / kg GroupOL Abatacept: Original 2 mg / kg GroupOL Abatacept: Original Placebo Group
Change from BL at Day 360 (n=74, 59, 60)-38.24 ± 5.95-25.66 ± 7.835.00 ± 6.72
Change from BL at Day 720 (n=71, 53, 53)-28.20 ± 8.61-45.06 ± 9.27-20.89 ± 7.73
Change from BL at Day 1080 (n=59, 45, 45)-33.10 ± 13.08-52.87 ± 12.86-15.87 ± 11.18
Change from BL at Day 1440 (n=54, 37, 37)-30.52 ± 9.75-52.49 ± 16.32-4.41 ± 12.28
Change from BL at Day 1800 (n=50, 38, 34)-20.06 ± 26.97-65.95 ± 16.26-25.68 ± 12.18
SecondaryParticipants With Laboratory Abnormalities Meeting the Marked Abnormality Criteria for Selected Hematologic Values During Double-Blind Therapy
Time frame:
From the start of study up to 60 days post the end of the 12-month double-blind period
Reported as:
Number · Participants
Participants With Laboratory Abnormalities Meeting the Marked Abnormality Criteria for Selected Hematologic Values During Double-Blind Therapy
ParticipantsDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + Methotrexate
Low Hemoglobin (n=115, 104, 119)103
Low Platelets (n=114, 104, 119)000
High Platelets (n=114, 104, 119)000
Low Leukocytes (n=115, 104, 119)000
High Leukocytes (n=115, 104, 119)12614
Low Neutrophils (n=115, 105, 119)010
SecondaryNumber of Participants Who Discontinued Due to Lack of Efficacy in the DB and OL Periods
Time frame:
Day 1 to Day 360 (Double-Blind Period), Day 361 to Day 3060 (Open-Label Period)
Reported as:
Number · participants
Number of Participants Who Discontinued Due to Lack of Efficacy in the DB and OL Periods
participantsDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + MethotrexateOpen-Label (OL) Abatacept (10 mg / kg)
Number of Participants Who Discontinued Due to Lack of Efficacy in the DB and OL Periods12162826
SecondaryImmunogenicity Data: Anti-CTLA4Ig Antibodies With Immunoglobulin (IG) Region
Time frame:
Baseline, Days 30, 90, 180, 270, 360
Reported as:
Geometric mean · titers
Immunogenicity Data: Anti-CTLA4Ig Antibodies With Immunoglobulin (IG) Region
titersDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate
Baseline for Day 30 Cohort (n=110, 100)9151.8 ± 10692.688861.8 ± 9282.06
Day 30 (n=110, 100)8361.5 ± 9931.798561.7 ± 9323.91
Baseline for Day 90 Cohort (n=110, 99)9052.8 ± 10392.268930.2 ± 9002.57
Day 90 (n=110, 99)6842.3 ± 7659.017497.8 ± 7356.42
Baseline for Day 180 Cohort (n=102, 90)8853.6 ± 10330.928689.3 ± 8626.90
Day 180 (n=102, 90)5967.3 ± 6535.577016.5 ± 6945.59
Baseline for Day 270 Cohort (n=94, 73)13149.7 ± 14850.0711976.7 ± 13679.48
Day 270 (n=94, 73)8027.5 ± 8863.479725.9 ± 11337.20
Baseline for Day 360 Cohort (n=83, 74)13287.8 ± 15024.7811712.4 ± 12971.16
Day 360 (n=83, 74)8675.1 ± 10038.7610284.1 ± 12175.48
SecondaryImmunogenicity Data: Anti-CTLA4Ig Antibodies Without IG Region
Time frame:
Baseline, Days 30, 90, 180, 270, 360
Reported as:
Geometric mean · titers
Immunogenicity Data: Anti-CTLA4Ig Antibodies Without IG Region
titersDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate
Baseline for Day 30 Cohort (n=110, 101)12.6 ± 9.5911.7 ± 4.79
Day 30 (n=110, 101)12.5 ± 9.3812.0 ± 5.58
Baseline for Day 90 Cohort (n=110, 99)12.5 ± 9.4211.6 ± 4.69
Day 90 (n=110, 99)12.0 ± 8.3111.4 ± 3.96
Baseline for Day 180 Cohort (n=102, 90)12.6 ± 9.9111.6 ± 4.76
Day 180 (n=102, 90)12.1 ± 8.6611.7 ± 5.01
Baseline for Day 270 Cohort (n=95, 73)13.4 ± 10.5112.1 ± 5.22
Day 270 (n=95, 73)12.5 ± 8.7011.7 ± 4.42
Baseline for Day 360 Cohort (n=84, 76)13.6 ± 11.0312.2 ± 5.77
Day 360 (n=84, 76)12.9 ± 9.7911.6 ± 4.42
SecondaryImmunogenicity Data: Categories of Post Baseline Value to Baseline Value (VA/PRE) Ratios and Number of Participants With Sero-conversion (Anti-CTLA4Ig Antibodies With IG Region)

Number of participants with ratio of VA/PRE \<=3, \<3 to \<=9, and \>9. Ratios greater than 9 are incidences of Anti-CTLA4Ig sero-conversion.

Time frame:
Baseline, Days 30, 90, 180, 270, 360
Reported as:
Number · participants
Immunogenicity Data: Categories of Post Baseline Value to Baseline Value (VA/PRE) Ratios and Number of Participants With Sero-conversion (Anti-CTLA4Ig Antibodies With IG Region)
participantsDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate
Day 30, ratio <=3 (n=110, 100)109100
Day 30, ratio <3 to <=9 (n=110, 100)10
Day 30, ratio >9 (n=110, 100)00
Day 90, ratio <=3 (n=110, 99)11099
Day 90, ratio <3 to <=9 (n=110, 99)00
Day 90, ratio >9 (n=110, 99)00
Day 180, ratio <=3 (n=102, 90)10190
Day 180, ratio <3 to <=9 (n=102, 90)10
Day 180, ratio >9 (n=102, 90)00
Day 270, ratio <=3 (n=94, 73)9473
Day 270, ratio <3 to <=9 (n=94, 73)00
Day 270, ratio >9 (n=94, 73)00
Day 360, ratio <=3 (n=83, 74)8172
Day 360, ratio <3 to <=9 (n=83, 74)22
Day 360, ratio >9 (n=83, 74)00
PrimaryBaseline Immunoglobulin G (IgG) Over Time in OL Period

Time-matched baseline (Day 0) values and post-baseline vales were presented for each post-baseline visit and represent only that cohort of participants with measurements available at that post-baseline assessment. Mean Change from Baseline data for these cohorts are presented in Outcome Measure 8.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440 and 1800
Reported as:
Mean · mg/dL
Baseline Immunoglobulin G (IgG) Over Time in OL Period
mg/dLOL Abatacept: Original 10 mg / kg GroupOL Abatacept: Original 2 mg / kg GroupOL Abatacept: Original Placebo Group
Baseline for Day 360 cohort (n=75, 59, 60)1130.31 ± 295.281086.05 ± 263.411079.00 ± 345.72
Baseline for Day 720 cohort (n=72, 53, 53)1138.58 ± 303.241093.23 ± 318.241076.40 ± 333.08
Baseline for Day 1080 cohort (n=60, 45, 45)1145.15 ± 305.511053.91 ± 264.531136.27 ± 372.58
Baseline for Day 1440 cohort (n=55, 37, 37)1154.58 ± 315.001095.49 ± 261.861135.43 ± 381.72
Baseline for Day 1800 cohort (n=51, 38, 34)1152.63 ± 305.011092.76 ± 260.851137.21 ± 368.39
PrimaryMean Change From Baseline (BL) in IgG Over Time in OL Period

Blood samples for immunoglobulin assessments were obtained to determine change from baseline in serum IgG. Baseline data for these cohorts are presented in Outcome Measure 7.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, and 1800
Reported as:
Mean · mg/dL
Mean Change From Baseline (BL) in IgG Over Time in OL Period
mg/dLOL Abatacept: Original 10 mg / kg GroupOL Abatacept: Original 2 mg / kg GroupOL Abatacept: Original Placebo Group
Change from BL at Day 360 (n=75, 59, 60)-181.92 ± 19.78-110.71 ± 21.46-15.12 ± 21.71
Change from BL at Day 720 (n=72, 53, 53)-183.04 ± 28.58-168.55 ± 31.82-137.06 ± 31.62
Change from BL at Day 1080 (n=60, 45, 45)-199.58 ± 33.68-229.91 ± 26.75-150.40 ± 33.97
Change from BL at Day 1440 (n=55, 37, 37)-228.11 ± 28.90-279.14 ± 33.43-147.46 ± 45.84
Change from BL at Day 1800 (n=51, 38, 34)-217.43 ± 39.52-206.21 ± 39.10-187.94 ± 44.40
PrimaryBaseline Immunoglobulin M (IgM) Over Time in OL Period

Time-matched baseline (Day 0) values and post-baseline values were presented for each post-baseline visit and represent only that cohort of participants with measurements available at that post-baseline assessment. Mean Change from Baseline data for these cohorts are presented in Outcome Measure 10.

Time frame:
Baseline (Day 0) and Days 360, 720,1080,1440, and 1800
Reported as:
Mean · mg/dL
Baseline Immunoglobulin M (IgM) Over Time in OL Period
mg/dLOL Abatacept: Original 10 mg / kg GroupOL Abatacept: Original 2 mg / kg GroupOL Abatacept: Original Placebo Group
Baseline for Day 360 cohort (n=74, 59, 60)147.76 ± 76.05134.29 ± 66.81125.10 ± 52.12
Baseline for Day 720 cohort (n=71, 53, 53)147.76 ± 76.31137.79 ± 69.93123.25 ± 52.79
Baseline for Day 1080 cohort (n=59, 45, 45)144.75 ± 78.89127.36 ± 68.06129.04 ± 54.79
Baseline for Day 1440 cohort (n=54, 37, 37)141.69 ± 77.90136.22 ± 70.90133.51 ± 58.04
Baseline for Day 1800 cohort (n=45, 33, 32)133.22 ± 61.79124.15 ± 67.07124.63 ± 58.69
SecondaryImmunogenicity Data: Categories of Post Baseline Value to Baseline Value (VA/PRE) Ratios and Number of Participants With Sero-conversion(Anti-CTLA4Ig Antibodies Without IG Region)

Number of participants with ratio of VA/PRE \<=3, \<3 to \<=9, and \>9. Ratios greater than 9 are incidences of Anti-CTLA4Ig sero-conversion.

Time frame:
Baseline, Days 30, 90, 180, 270, 360
Reported as:
Number · participants
Immunogenicity Data: Categories of Post Baseline Value to Baseline Value (VA/PRE) Ratios and Number of Participants With Sero-conversion(Anti-CTLA4Ig Antibodies Without IG Region)
participantsDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + Methotrexate
Day 30, ratio <=3 (n=110, 101)10899
Day 30, ratio <3 to <=9 (n=110, 101)12
Day 30, ratio >9 (n=110, 101)10
Day 90, ratio <=3 (n=110, 99)11099
Day 90, ratio <3 to <=9 (n=110, 99)00
Day 90, ratio >9 (n=110, 99)00
Day 180, ratio <=3 (n=102, 90)10189
Day 180, ratio <3 to <=9 (n=102, 90)10
Day 180, ratio >9 (n=102, 90)01
Day 270, ratio <=3 (n=95, 73)9573
Day 270, ratio <3 to <=9 (n=95, 73)00
Day 270, ratio >9 (n=95, 73)00
Day 360, ratio <=3 (n=84, 76)8476
Day 360, ratio <3 to <=9 (n=84, 76)00
Day 360, ratio >9 (n=84, 76)00
SecondaryPharmacodynamic Measure: Mean Changes From Baseline in Rheumatoid Factor at Day 180 and Day 360
Time frame:
Baseline, Day 180, Day 360
Reported as:
Mean · IU/mL
Pharmacodynamic Measure: Mean Changes From Baseline in Rheumatoid Factor at Day 180 and Day 360
IU/mLDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + Methotrexate
Mean Change at Day 180 (n=95, 84, 74)-104.3 (-151.5 to 57.0)-28.1 (-52.1 to -4.1)-0.6 (-31.7 to 30.4)
Mean Change at Day 360 (n=69, 54, 57)-118.3 (-175.2 to -61.4)-23.6 (-56.8 to 9.7)20.9 (-11.3 to 53.1)
SecondaryPharmacodynamic Measure: Mean Changes From Baseline in Interleukin-6 at Day 180 and Day 360
Time frame:
Baseline, Day 180, Day 360
Reported as:
Mean · pg/mL
Pharmacodynamic Measure: Mean Changes From Baseline in Interleukin-6 at Day 180 and Day 360
pg/mLDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + Methotrexate
Mean Change at Day 180 (n=85, 74, 68)-20.5 (-27.8 to -13.2)-16.1 (-24.2 to -8.0)1.3 (-7.9 to 10.5)
Mean Change at Day 360 (n=56, 47, 47)-20.9 (-31.6 to -10.2)-12.7 (-22.5 to -2.9)-0.6 (-8.1 to 6.9)
SecondaryPharmacodynamic Measure: Mean Changes From Baseline in Plasma Soluble Interleukin-2 Receptor (sIL-2R) at Day 180 and Day 360
Time frame:
Baseline, Day 180, Day 360
Reported as:
Mean · pg/mL
Pharmacodynamic Measure: Mean Changes From Baseline in Plasma Soluble Interleukin-2 Receptor (sIL-2R) at Day 180 and Day 360
pg/mLDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + Methotrexate
Mean Change at Day 180 (n=94, 84, 76)-315.9 (-418.5 to -213.3)-135.5 (-241.5 to -29.5)43.6 (-71.2 to 158.4)
Mean Change at Day 360 (n=68, 55, 54)-194.3 (-305.7 to -83.0)40.4 (-71.5 to 152.3)196.8 (24.3 to 369.4)
SecondaryPharmacodynamic Measure: Mean Changes From Baseline in E-Selectin at Day 180 and Day 360
Time frame:
Baseline, Day 180, Day 360
Reported as:
Mean · ng/mL
Pharmacodynamic Measure: Mean Changes From Baseline in E-Selectin at Day 180 and Day 360
ng/mLDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + Methotrexate
Mean Change at Day 180 (n=88, 80, 71)-8.3 (-13.2 to -3.4)0.5 (-6.0 to 7.0)-0.7 (-6.9 to 5.5)
Mean Change at Day 360 (n=75, 67, 61)-10.9 (-15.7 to -6.1)0.6 (-6.0 to 9.0)2.0 (-4.9 to 9.0)
SecondaryPharmacodynamic Measure: Mean Changes From Baseline in Soluble Inter-Cellular Adhesion Molecule 1 (sICAM-1) at Day 180 and Day 360
Time frame:
Baseline, Day 180, Day 360
Reported as:
Mean · ng/mL
Pharmacodynamic Measure: Mean Changes From Baseline in Soluble Inter-Cellular Adhesion Molecule 1 (sICAM-1) at Day 180 and Day 360
ng/mLDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + Methotrexate
Mean Change at Day 180 (n=94, 82, 75)-40.6 (-58.5 to -22.8)-6.2 (-27.5 to 15.1)1.1 (-31.9 to 34.1)
Mean Change at Day 360 (n=77, 67, 63)-55.2 (-74.8 to -35.5)-13.6 (-36.3 to 9.0)0.7 (-27.6 to 28.9)
SecondaryPharmacodynamic Measure: Mean Changes From Baseline in Tumor Necrosis Factor (TNF)-Alpha at Day 180 and Day 360
Time frame:
Baseline, Day 180, Day 360
Reported as:
Mean · ng/mL
Pharmacodynamic Measure: Mean Changes From Baseline in Tumor Necrosis Factor (TNF)-Alpha at Day 180 and Day 360
ng/mLDouble-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + Methotrexate
Mean Change at Day 180 (n=83, 74, 68)-3.7 (-8.7 to 1.3)-1.2 (-4.3 to 1.9)-3.6 (-8.0 to 0.7)
Mean Change at Day 360 (n=61, 48, 49)-3.0 (-8.7 to 2.7)1.1 (-1.3 to 3.4)-0.3 (-3.2 to 2.7)
SecondaryNumber of ACR 20 Responders in OL Period

ACR 20 response requires a participant to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in Health Assessment Questionnaire score. A participant achieved a sustained ACR 20 response if the participant had ACR 20 observed for at least 2 consecutive study visits.

Time frame:
Days 360, 450, 540, 630, 720, 810, 900, 1080, 1350, 1440, 1530, 1620, 1710, 1800, 1980, 2160, 2340, 2520, 2700, 2880, and 3060
Reported as:
Number · Participants
Number of ACR 20 Responders in OL Period
ParticipantsOL Abatacept: Original 10 mg/kg GroupOL Abatacept: Original 2 mg/kg GroupOL Abatacept: Original Placebo Group
Day 360 (n=84, 68, 67)644037
Day 450 (n=83, 67, 66)564546
Day 540 (n=82, 65, 59)614545
Day 630 (n=79, 63, 59)604444
Day 720 (n=75, 59, 56)583943
Day 810 (n=73, 56, 54)494144
Day 900 (n=69, 53, 51)564242
Day 990 (n=66, 52, 51)523940
Day 1080 (n=66, 50, 49)483935
Day 1170 (n=65, 50, 49)463536
Day 1260 (n=64, 49, 46)484139
Day 1350 (n=62, 48, 44)463037
Day 440 (n=61, 47, 44)433837
Day 1530 (n=60, 46, 43)453529
Day 1620 (n=58, 45, 43)443538
Day 1710 (n=58, 45, 42)373438
Day 1800 (n=56, 44, 42)443238
Day 1980 (n=53, 44, 40)373428
Day 2160 (n=49, 42, 38)393332
Day 2340 (n=47, 36, 36)352728
Day 2520 (n=43, 37, 33)313028
Day 2700 (n=37, 34, 34)332623
Day 2880 (n=36, 31, 32)282827
Day 3060 (n=18, 18, 17)131314
SecondaryNumber of ACR 50 Responders in the OL Period

ACR 50 response requires a participant to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 50 response if the participant had ACR 50 observed for at least 2 consecutive study visits.

Time frame:
Days 360, 450, 540, 630, 720, 810, 900, 1080, 1350, 1440, 1530, 1620, 1710, 1800, 1980, 2160, 2340, 2520, 2700, 2880, and 3060
Reported as:
Number · Participants
Number of ACR 50 Responders in the OL Period
ParticipantsOL Abatacept: Original 10 mg/kg GroupOL Abatacept: Original 2 mg/kg GroupOL Abatacept: Original Placebo Group
Day 360 (n=84, 68, 67)442321
Day 450 (n=83, 67, 66)413030
Day 540 (n=82, 65, 59)382831
Day 630 (n=79, 63, 59)382731
Day 720 (n=75, 59, 56)432934
Day 810 (n=73, 56, 54)422330
Day 900 (n=69, 53, 51)403429
Day 990 (n=66, 52, 51)402831
Day 1,080 (n=66, 50, 49)352429
Day 1,170 (n=65, 50, 49)362729
Day 1,260 (n=64, 49, 46)332428
Day 1,350 (n=62, 48, 44)282428
Day 1,440 (n=61, 47, 44)253324
Day 1,530 (n=60, 46, 43)332826
Day 1,620 (n=58, 45, 43)292726
Day 1,710 (n=58, 45, 42)232725
Day 1,800 (n=56, 44, 42)342828
Day 1,980 (n=53, 44, 40)312622
Day 2,160 (n=49, 42, 38)253025
Day 2,340 (n=47, 36, 36)241521
Day 2,520 (n=43, 37, 33)252321
Day 2,700 (n=37, 34, 34)231917
Day 2,880 (n=36, 31, 32)231819
Day 3,060 (n=18, 18, 17)8109
SecondaryNumber of ACR 70 Responders in the OL Period

ACR 70 response requires a participant to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in 3 of the following 5 parameters: physician global assessment of disease, participant global assessment of disease, participant assessment of pain, C-reactive protein or erythrocyte sedimentation rate, and degree of disability in HAQ score. A participant achieved a sustained ACR 70 response if the participant had ACR 70 observed for at least 2 consecutive study visits.

Time frame:
Days 360, 450, 540, 630, 720, 810, 900, 1080, 1350, 1440, 1530, 1620, 1710, 1800, 1980, 2160, 2340, 2520, 2700, 2880, and 3060
Reported as:
Number · Participants
Number of ACR 70 Responders in the OL Period
ParticipantsOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Day 360 (n=84, 68, 67)24139
Day 450 (n=83, 67, 66)211412
Day 540 (n=82, 65, 59)281512
Day 630 (n=79, 63, 59)251715
Day 720 (n=75, 59, 56)221816
Day 810 (n=73, 56, 54)201411
Day 900 (n=69, 53, 51)191615
Day 990 (n=66, 52, 51)231717
Day 1080 (n=66, 50, 49)211816
Day 1170 (n=65, 50, 49)231617
Day 1260 (n=64, 49, 46)201220
Day 1350 (n=62, 48, 44)181313
Day 1440 (n=61, 47, 44)191615
Day 1530 (n=60, 46, 43)221613
Day 1620 (n=58, 45, 43)211516
Day 1710 (n=58, 45, 42)151812
Day 1800 (n=56, 44, 42)211715
Day 1980 (n=53, 44, 40)251610
Day 2160 (n=49, 42, 38)231811
Day 2340 (n=47, 36, 36)191114
Day 2520 (n=43, 37, 33)191611
Day 2700 (n=37, 34, 34)201212
Day 2880 (n=36, 31, 32)171012
Day 3060 (n=18, 18, 17)667
SecondaryNumber of Participants With a Clinically Meaningful Improvement on the Modified Health Assessment Questionnaire (mHAQ) in OL Period

The mHAQ is a self-administered questionnaire composed of 20 questions that assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The answers are graded on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The HAQ disease index is a weighted sum of the scale scores, with a higher score indicating poorer function. A clinically meaningful improvement was defined as a reduction from baseline in mHAQ score of at least 0.30 units.

Time frame:
Days 360, 720,1080, 1440, 1800, 2160, 2520, 2880, and 3060
Reported as:
Number · Participants
Number of Participants With a Clinically Meaningful Improvement on the Modified Health Assessment Questionnaire (mHAQ) in OL Period
ParticipantsOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Day 360 (n=84, 68, 67)463023
Day 720 (n=75, 59, 56)393421
Day 1080 (n=66, 50, 49)342828
Day 1440 (n=61, 47, 44)312620
Day 1800 (n=56, 44, 42)292720
Day 2160 (n=49, 42, 38)262415
Day 2520 (n=43, 37, 33)232117
Day 2880 (n=36, 31, 32)182114
Day 3060 (n=18, 18, 17)885
SecondaryBaseline Level of Serum Rheumatoid Factor Over Time in OL Period

Serum evaluations were carried out to determine participant baseline rheumatoid factor serum concentration. Time-matched baseline(Day 0) values and post-baseline vales were presented for each post-baseline visit and represent only that cohort of participants with measurements available at that post-baseline assessment.

Time frame:
Baseline (Day 0) and Days 360, 720,1080, 1440, 1800, 2160, 2520, 2880, and 3060
Reported as:
Mean · IU/mL
Baseline Level of Serum Rheumatoid Factor Over Time in OL Period
IU/mLOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Baseline for Day 360 cohort (n=80, 62, 65)291.98 ± 374.41219.24 ± 262.55233.57 ± 299.75
Baseline for Day 720 cohort (n=69, 57, 54)256.12 ± 361.74217.21 ± 267.03227.81 ± 308.53
Baseline for Day 1080 cohort (n=64, 49, 47)233.95 ± 346.73172.00 ± 204.63203.94 ± 250.44
Baseline for Day 1440 cohort (n=57, 41, 41)243.32 ± 363.86165.39 ± 173.31215.71 ± 258.60
Baseline for Day 1800 cohort (n=51, 41, 40)165.39 ± 152.94175.41 ± 206.37205.33 ± 254.25
Baseline for Day 2160 (n=43, 34, 30)185.74 ± 173.26181.91 ± 216.48194.17 ± 254.30
Baseline for Day 2520 (n=23, 24, 22)175.13 ± 156.99158.42 ± 210.74269.55 ± 309.15
Baseline for Day 2880 (n=15, 16, 13)159.93 ± 123.69197.63 ± 251.82366.38 ± 362.39
Baseline for Day 3060 (n=7, 9, 5)214.29 ± 120.00223.44 ± 316.59232.60 ± 202.38
SecondaryMean Change From Baseline in Serum Rheumatoid Factor Level Over Time in OL Period

Serum evaluations were carried out to determine participant change from baseline in rheumatoid factor serum concentration. Mean change from baseline = value at post-baseline OL time point-value and baseline OL time point.

Time frame:
Baseline (Day 0) and Days 360, 720,1080, 1440, 1800, 2160, 2520, 2880, and 3060
Reported as:
Mean · IU/mL
Mean Change From Baseline in Serum Rheumatoid Factor Level Over Time in OL Period
IU/mLOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Change at Day 360 (n=80, 62, 65)-72.78 ± 39.69-21.71 ± 14.507.77 ± 21.05
Change at Day 720 (n=69, 57, 54)37.51 ± 76.03-40.23 ± 23.05-48.37 ± 48.47
Change at Day 1080 (n=64, 49, 47)8.53 ± 66.71-34.78 ± 24.22-0.04 ± 38.15
Change at Day 1440 (n=57, 41, 41)43.81 ± 97.15-15.68 ± 32.261.54 ± 49.24
Change at Day 1800 (n=51, 41, 40)30.29 ± 30.7810.95 ± 41.17-49.83 ± 40.58
Change at Day 2160 (n=43, 34, 30)-8.44 ± 45.19-26.29 ± 35.06-65.50 ± 51.49
Change at Day 2520 (n=23, 24, 22)87.61 ± 99.50-54.92 ± 41.93-50.05 ± 70.38
Change at Day 2880 (n=15, 16, 13)28.47 ± 45.91-102.06 ± 64.6246.54 ± 193.55
Change at Day 3060 (n=7, 9, 5)-45.14 ± 88.72-89.00 ± 109.53118.40 ± 252.72
PrimaryMean Change From Baseline (BL) in IgM in OL Period

Blood samples for immunoglobulin assessments were obtained to determine change from baseline in serum IgM. Baseline data for these time-matched cohorts are presented in Outcome Measure 9.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, and 1800
Reported as:
Mean · mg/dL
Mean Change From Baseline (BL) in IgM in OL Period
mg/dLOL Abatacept: Original 10 mg/kg GroupOL Abatacept: Original 2 mg/kg GroupOL Abatacept: Original Placebo Group
Change from BL at Day 360 (n=74, 59, 60)-5.81 ± 3.493.22 ± 4.3611.17 ± 3.89
Change from BL at Day 720 (n=71, 53, 53)12.68 ± 7.320.11 ± 4.766.45 ± 6.11
Change from BL at Day 1080 (n=59, 45, 45)0.37 ± 6.691.93 ± 6.6127.93 ± 11.62
Change from BL at Day 1440 (n=54, 37, 37)2.52 ± 7.070.68 ± 8.9914.46 ± 9.52
Change from BL at Day 1,800 (n=45, 33, 32)7.84 ± 6.899.06 ± 7.556.72 ± 8.80
PrimaryNumber of Participants With Hematology Values Meeting Marked Abnormality Criteria in OL Period
Time frame:
Day 360 to Day 3060
Reported as:
Number · Participants
Number of Participants With Hematology Values Meeting Marked Abnormality Criteria in OL Period
ParticipantsOL Abatacept (10 mg / kg)
Low Hemoglobin (> 13.0 grams/dL; n=216)21
Low Hematocrit (< 35%; n=216)11
Low Platelet Count (<145*10^9 cells/L; n=214)1
High Platelet Count (>400*10^9 cells/L; n=214)1
Low Leukocytes (<3.60 *10^3 cells/µL; n=216)12
High Leukocytes (>10.30*10^3 cells/µL; n=216)49
Low Neutrophils + Bands (<2.0*10^3 c/uL; n=217)1
Low Absolute Lymphocytes(<1.0*10^3cells/µL; n=217)48
High Absolute Lymphocytes(>3.5*10^3cells/µL;n=217)0
High Absolute Monocytes (>720*10^3cells/µL; n=217)0
High Absolute Basophils(>0.2*10^3 cells/µL; n=217)1
High Absolute Eosinophils(>0.4*10^3cells/µL;n=217)21
PrimaryNumber of Participants With Liver and Kidney Function Values Meeting Marked Abnormality Criteria in OL Period
Time frame:
Day 360 to Day 3060
Reported as:
Number · Participants
Number of Participants With Liver and Kidney Function Values Meeting Marked Abnormality Criteria in OL Period
ParticipantsOL Abatacept (10 mg / kg)
High Alkaline Phosphatase (>117 IU/L)1
High Aspartate Aminotransferase (>38 IU/L)6
High Alanine Aminotransferase (>30 IU/L)5
High G-Glutamyl Transferase (>61 IU/L)20
High Total Bilirubin (>1.1 mg/dL)0
High Blood Urea Nitrogen (>21.3 mg/dL)14
High Creatinine (>1.30 mg/dL)13
PrimaryNumber of Participants With Electrolyte Values Meeting Marked Abnormality Criteria in OL Period
Time frame:
Day 360 to Day 3060
Reported as:
Number · Participants
Number of Participants With Electrolyte Values Meeting Marked Abnormality Criteria in OL Period
ParticipantsOL Abatacept (10 mg / kg)
Low Serum Sodium (<135 mEq/L; n=217)4
High Serum Sodium (>145 mEq/L; n=217)10
Low Serum Potassium (<3.5 mEq/L; n=217)8
High Serum Potassium (>5.0 mEq/L; n=217)10
Low Serum Chloride (<97 mEq/L; n=217)8
High Serum Chloride (>106 mEq/L; n=217)3
Low Total Calcium (<8.6 mg/dL; n=217)0
High Total Calcium (>10.2 mg/dL; n=217)3
Low Inorganic Phosphorus (<2.7 mg/dL; n=217)5
High Inorganic Phosphorus (> 4.5 mg/dL; n=217)11
SecondaryMean Baseline Soluble Serum Interleukin-2 Receptor Level (sIL2-r) Over Time in OL Period

Serum evaluations were carried out to determine participant serum levels of sIL2-r at baseline. Time-matched baseline (Day 0) values and post-baseline vales were presented for each post-baseline visit and represent only that cohort of participants with measurements available at that post-baseline assessment.

Time frame:
Baseline (Day 0) and Days 360, 720,1080, 1440, 1800, 2160, 2520, 2880, and 3060
Reported as:
Mean · pg/mL
Mean Baseline Soluble Serum Interleukin-2 Receptor Level (sIL2-r) Over Time in OL Period
pg/mLOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg /kgOL Abatacept: Original Placebo
Baseline for Day 360 cohort (n=69, 57, 58)1424.86 ± 790.751365.40 ± 524.901480.93 ± 713.88
Baseline for Day 720 cohort (n=66, 53, 49)1419.82 ± 721.001351.15 ± 497.641437.24 ± 730.73
Baseline for Day 1080 cohort (n=57, 47, 44)1413.28 ± 760.391341.51 ± 520.061392.09 ± 678.85
Baseline for Day 1440 cohort (n=47, 36, 31)1418.64 ± 806.851323.14 ± 538.821409.71 ± 687.86
Baseline for Day 1800 cohort (n=27, 13, 17)1252.04 ± 572.141160.15 ± 444.371476.06 ± 590.14
PrimaryNumber of Participants With Glucose, Protein, Metabolites, and Urinalysis Values Meeting Marked Abnormality Criteria in OL Period
Time frame:
Day 360 to Day 3060
Reported as:
Number · Participants
Number of Participants With Glucose, Protein, Metabolites, and Urinalysis Values Meeting Marked Abnormality Criteria in OL Period
ParticipantsOL Abatacept (10 mg / kg)
Low Serum Glucose (< 70 mg/dL; n=217)33
High Serum Glucose (> 110 mg/dL; n=217)30
Low Fasting Serum Glucose (< 70 mg/dL; n=1)0
High Fasting Serum Glucose (> 110 mg/dL; n=1)0
Low Total Protein (< 6.2 grams/dL; n=217)12
High Total Protein (>8.3 grams/dL; n=217)1
Low Albumin (<3.5 grams/dL; n=217)7
High Uric Acid (>7.6 mg/dL; n=217)2
High Urine Protein (> trace; n=217)29
High Urine Glucose (> trace; n=217)32
High Urine Blood (> trace; n=217)47
High Urine White Blood Cell Count (> trace; n=162)74
High Urine Red Blood Cell Count (> trace; n=162)51
SecondaryMean Change From Baseline in sIL2-r Over Time in OL Period

Serum evaluations were carried out to determine participant serum levels of sIL2-r. Mean change from baseline=value at post-baseline OL time point-value and baseline OL time point.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, and 1800
Reported as:
Mean · pg/mL
Mean Change From Baseline in sIL2-r Over Time in OL Period
pg/mLOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Change at Day 360 (n=69, 57, 58)-200.62 ± 56.4344.05 ± 60.80207.40 ± 91.17
Change at Day 720 (n=66, 53, 49)-323.26 ± 83.71-209.19 ± 60.08-213.22 ± 83.64
Change at Day 1080 (n=57, 47, 44)-158.93 ± 96.60-44.98 ± 95.04-156.20 ± 69.04
Change at Day 1440 (n=47, 36, 31)-421.57 ± 98.79-392.08 ± 81.78-394.45 ± 123.99
Change at Day 1800 (n=27, 13, 17)-249.81 ± 123.30-84.77 ± 61.61-247.12 ± 128.65
SecondaryMean Baseline Serum C-Reactive Protein Level Over Time in OL Period

Serum evaluations were carried out to evaluate participant serum CRP concentrations at baseline. Time-matched BL (Day 0) values and post-BL vales were presented for each post-BL visit and represent only that cohort of participants with measurements available at that post-BL assessment.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080,1440,1800, 2160, 2520, 2880, 3060
Reported as:
Mean · mg/dL
Mean Baseline Serum C-Reactive Protein Level Over Time in OL Period
mg/dLOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Baseline for Day 360 cohort (n=78, 65, 65)2.90 ± 2.253.02 ± 2.362.61 ± 2.20
Baseline for Day 720 cohort (n=68, 54, 53)2.64 ± 2.033.16 ± 2.602.60 ± 2.03
Baseline for Day 1080 cohort (n=61, 50, 47)2.58 ± 1.993.06 ± 2.632.52 ± 2.06
Baseline for Day 1440 cohort (n=56, 46, 41)2.65 ± 2.023.11 ± 2.712.62 ± 2.16
Baseline for Day 1800 cohort (n=52, 41, 41)2.40 ± 1.733.10 ± 2.752.64 ± 2.15
Baseline for Day 2160 cohort (n=43, 34, 33)2.34 ± 1.662.91 ± 2.772.80 ± 2.36
Baseline for Day 2520 cohort (n=36, 35, 32)2.46 ± 1.703.02 ± 2.792.86 ± 2.35
Baseline for Day 2880 cohort (n=27, 26, 27)2.14 ± 1.422.95 ± 3.003.08 ± 2.49
Baseline for Day 3060 cohort (n=14, 10, 8)1.93 ± 1.122.99 ± 3.072.72 ± 1.30
SecondaryMean Change From Baseline in Level of C Reactive Protein Over Time in OL Period

Serum evaluations were carried out to evaluate participant concentrations of serum C reactive protein. Mean change from baseline=value at post-baseline OL time point-value and baseline OL time point.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, 3060
Reported as:
Mean · mg/dL
Mean Change From Baseline in Level of C Reactive Protein Over Time in OL Period
mg/dLOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Change at Day 360 (n=78, 65, 65)-1.38 ± 0.29-1.13 ± 0.33-0.08 ± 0.38
Change at Day 720 (n=68, 54, 53)-1.46 ± 0.25-2.08 ± 0.38-1.26 ± 0.28
Change at Day 1080 (n=61, 50, 47)-0.96 ± 0.44-1.93 ± 0.38-1.20 ± 0.35
Change at Day 1440 (n=56, 46, 41)-1.56 ± 0.33-1.91 ± 0.37-1.21 ± 0.44
Change at Day 1800 (n=52, 41, 41)-1.53 ± 0.25-1.33 ± 0.83-1.72 ± 0.35
Change at Day 2160 (n=43, 34, 33)-1.33 ± 0.37-2.11 ± 0.46-2.04 ± 0.42
Change at Day 2520 (n=36, 35, 32)-1.45 ± 0.39-2.29 ± 0.48-2.01 ± 0.40
Change at Day 2880 (n=27, 26, 27)-1.47 ± 0.34-2.16 ± 0.61-2.25 ± 0.49
Change at Day 3060 (n=14, 10, 8)-1.06 ± 0.36-2.10 ± 1.00-1.73 ± 0.50
SecondaryMean Baseline Physical Component Summary (PCS) of the Short-Form 36 (SF-36) Over Time in OL Period

SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 50.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2880, and 3060
Reported as:
Mean · Units on a Scale
Mean Baseline Physical Component Summary (PCS) of the Short-Form 36 (SF-36) Over Time in OL Period
Units on a ScaleOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Baseline for Day 360 cohort (n=84, 66, 64)30.90 ± 8.1431.03 ± 8.8732.57 ± 7.94
Baseline for Day 720 cohort (n=73, 55, 53)31.44 ± 8.3530.83 ± 8.0332.48 ± 7.14
Baseline for Day 1080 cohort (n=63, 50, 49)31.56 ± 8.1431.73 ± 8.6332.38 ± 7.08
Baseline for Day 1440 cohort (n=59, 46, 44)31.46 ± 8.3131.80 ± 8.8432.20 ± 7.44
Baseline for Day 1800 cohort (n=54, 43, 42)32.19 ± 8.7232.02 ± 8.9132.36 ± 7.57
Baseline for Day 2160 cohort (n=45, 36, 35)32.15 ± 8.7232.25 ± 9.0732.29 ± 7.70
Baseline for Day 2520 cohort (n=38, 35, 33)31.93 ± 9.5032.75 ± 9.2032.54 ± 7.39
Baseline for Day 2880 cohort (n=33, 30, 31)32.63 ± 8.7133.65 ± 8.6632.66 ± 7.81
Baseline for Day 3060 cohort (n=17, 17, 16)36.81 ± 7.6833.88 ± 9.1233.40 ± 9.52
SecondaryMean Change From Baseline (BL) in the Physical Component Summary (PCS) of the SF-36 Over Time in OL Period

The SF-36 consists of 2 summaries, the PCS and the MCS, and 8 individual indexes. The MCS addresses 4 of the 8 individual indices: vitality, social functioning, role-emotional, and mental health. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from baseline=value at post-baseline OL time point-value and baseline OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 49.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2880, and 3060
Reported as:
Mean · Units on a Scale
Mean Change From Baseline (BL) in the Physical Component Summary (PCS) of the SF-36 Over Time in OL Period
Units on a ScaleOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Change from BL on Day 360 (n=84, 66, 64)9.66 ± 1.057.13 ± 0.994.53 ± 1.04
Change from BL on Day 720 (n=73, 55, 53)9.15 ± 1.178.48 ± 1.258.30 ± 1.10
Change from BL on Day 1080 (n=63, 50, 49)9.28 ± 1.228.14 ± 1.369.28 ± 1.29
Change from BL on Day 1440 (n=59, 46, 44)8.18 ± 1.339.53 ± 1.289.50 ± 1.29
Change from BL on Day 1800 (n=54, 43, 42)9.30 ± 1.497.60 ± 1.259.18 ± 1.20
Change from BL on Day 2160 (n=45, 36, 35)9.51 ± 1.7210.61 ± 1.448.86 ± 1.65
Change from BL on Day 2520 (n=38, 35, 33)10.12 ± 1.888.26 ± 1.587.92 ± 1.80
Change from BL on Day 2880 (n=33, 30, 31)10.97 ± 1.967.51 ± 1.359.19 ± 1.64
Change from BL on Day 3060 (n=17, 17, 16)8.55 ± 2.745.70 ± 1.989.06 ± 2.35
SecondaryMean Baseline Mental Component Summary (MCS) of the SF-36 Over Time in OL Period

SF-36=PCS, MCS, \& 8 individual indices. MCS addresses 4 of the 8 indices: vitality, social functioning, role-emotional, \& mental health. Subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched baseline (Day 0) values \& post-baseline (BL) values are presented for each post-BL visit \& represent only that cohort with measurements available at that post-BL assessment. See Outcome Measure 51 for Change from BL.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2880, and 3060
Reported as:
Mean · Units on a Scale
Mean Baseline Mental Component Summary (MCS) of the SF-36 Over Time in OL Period
Units on a ScaleOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Baseline (Day 0) for Day 360 cohort (n=84, 66, 64)46.27 ± 12.1342.10 ± 13.0844.44 ± 12.36
Baseline (Day 0) for Day 720 cohort (n=73,55, 53)46.17 ± 12.2441.82 ± 13.1044.74 ± 12.62
Baseline for Day 1080 cohort (n=63, 50, 49)45.45 ± 11.7642.10 ± 12.8244.53 ± 12.52
Baseline for Day 1440 cohort (n=59, 46, 44)45.32 ± 11.3842.48 ± 13.0644.66 ± 12.74
Baseline for Day 1800 cohort (n=54, 43, 42)45.07 ± 11.3141.87 ± 12.9944.68 ± 12.85
Baseline for Day 2160 cohort (n=45, 36, 35)45.57 ± 11.4542.09 ± 12.9643.89 ± 12.36
Baseline for Day 2520 cohort (n=38, 35, 33)46.35 ± 12.0742.53 ± 13.3444.51 ± 12.09
Baseline for Day 2880 cohort (n=33, 30, 31)45.48 ± 11.4540.74 ± 12.0243.51 ± 11.20
Baseline for Day 3060 cohort (n=17, 17, 16)46.24 ± 13.2640.94 ± 13.4745.14 ± 12.42
SecondaryMean Change From Baseline (BL) in the MCS of the SF-36 Over Time in OL Period

The SF-36 consists of 2 summaries, the PCS and the MCS, and 8 individual indexes. The MCS addresses 4 of the 8 individual indices: vitality, social functioning, role-emotional, and mental health. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from baseline=value at post-baseline OL time point-value and baseline OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 51.

Time frame:
Baseline (Day 0) and Days 360, 450, 540, 630, 720, 810, 900, 1080, 1350, 1440, 1530, 1620, 1710, 1800, 1980, 2160, 2340, 2520, 2700, 2880, and 3060
Reported as:
Mean · Units on a Scale
Mean Change From Baseline (BL) in the MCS of the SF-36 Over Time in OL Period
Units on a ScaleOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg / kg GroupOL Abatacept: Original Placebo
Change from BL at Day 360 (n=84, 66, 64)6.05 ± 1.196.03 ± 1.322.53 ± 1.34
Change from BL at Day 720 (n=73,55, 53)4.59 ± 1.296.02 ± 1.494.17 ± 1.57
Change from BL at Day 1080 (n=63, 50, 49)4.01 ± 1.234.87 ± 1.445.52 ± 1.78
Change from BL at Day 1440 (n=59, 46, 44)4.67 ± 1.316.68 ± 1.344.76 ± 2.12
Change from BL at Day 1800 (n=54, 43, 42)5.32 ± 1.384.59 ± 1.662.26 ± 1.71
Change from BL at Day 2160 (n=45, 36, 35)6.22 ± 1.475.95 ± 1.464.55 ± 2.19
Change from BL at Day 2520 (n=38, 35, 33)2.81 ± 1.857.34 ± 1.754.44 ± 2.26
Change from BL at Day 2880 (n=33, 30, 31)5.00 ± 1.926.97 ± 1.693.87 ± 2.18
Change from BL at Day 3060 (n=17, 17, 16)4.81 ± 2.905.51 ± 2.881.91 ± 3.26
SecondaryMean Baseline (BL) Physical Functioning Domain of the SF-36 Over Time in OL Period

SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 54.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Reported as:
Mean · Units on a Scale
Mean Baseline (BL) Physical Functioning Domain of the SF-36 Over Time in OL Period
Units on a ScaleOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Baseline for Day 360 cohort (n=84, 67, 66)29.84 ± 9.5730.18 ± 10.2330.80 ± 9.48
Baseline for Day 720 cohort (n=73, 56, 53)30.39 ± 9.6330.58 ± 9.9930.79 ± 9.10
Baseline for Day 1080 cohort (n=64, 50, 49)30.27 ± 9.3831.21 ± 10.3530.95 ± 8.95
Baseline for Day 1440 cohort (n=60, 46, 44)30.47 ± 9.4331.50 ± 10.1231.26 ± 9.15
Baseline for Day 1800 cohort (n=54, 43, 42)30.96 ± 9.7431.81 ± 10.4531.48 ± 9.08
Baseline for Day 2160 cohort (n=45, 37, 35)31.41 ± 10.1632.24 ± 10.4231.56 ± 9.51
Baseline for Day 2520 cohort (n=38, 35, 33)31.47 ± 10.6432.79 ± 10.2632.04 ± 8.95
Baseline for Day 2880 cohort (n=33, 30, 31)31.77 ± 10.6233.56 ± 10.0732.18 ± 9.32
Baseline for Day 3060 cohort (n=18, 18, 16)34.97 ± 9.7433.92 ± 9.5532.37 ± 10.37
SecondaryMean Change From Baseline (BL) in the Physical Functioning Domain of the SF-36 Over Time in OL Period

SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 53.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Reported as:
Mean · Units on a Scale
Mean Change From Baseline (BL) in the Physical Functioning Domain of the SF-36 Over Time in OL Period
Units on a ScaleOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Change from BL at Day 360 (n=84, 67, 66)8.58 ± 1.116.53 ± 0.993.31 ± 0.92
Change from BL at Day 720 (n=73, 56, 53)8.36 ± 1.167.50 ± 1.327.30 ± 1.15
Change from BL at Day 1080 (n=64, 50, 49)8.36 ± 1.326.22 ± 1.497.62 ± 1.08
Change from BL at Day 1440 (n=60, 46, 44)7.91 ± 1.487.19 ± 1.487.58 ± 1.22
Change from BL at Day 1800 (n=54, 43, 42)8.39 ± 1.605.48 ± 1.456.16 ± 1.33
Change from BL at Day 2160 (n=45, 37, 35)9.24 ± 1.748.28 ± 1.535.46 ± 1.32
Change from BL at Day 2520 (n=38, 35, 33)7.92 ± 2.026.58 ± 1.745.87 ± 1.64
Change from BL at Day 2880 (n=33, 30, 31)9.93 ± 2.095.90 ± 1.636.63 ± 1.49
Change from BL at Day 3060 (n=18, 18, 16)6.21 ± 2.874.29 ± 1.916.16 ± 2.01
SecondaryMean Baseline Role-Physical Domain of the SF-36 Over Time in OL Period

SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 56.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Reported as:
Mean · Units on a Scale
Mean Baseline Role-Physical Domain of the SF-36 Over Time in OL Period
Units on a ScaleOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Baseline for Day 360 cohort (n=84, 66, 66)33.68 ± 9.6631.70 ± 7.7734.17 ± 8.82
Baseline for Day 720 cohort (n=73, 56, 53)34.06 ± 10.0931.49 ± 7.5133.69 ± 8.78
Baseline for Day 1080 cohort (n=64, 50, 49)34.36 ± 10.2232.20 ± 7.9633.58 ± 8.42
Baseline for Day 1440 cohort (n=60, 46, 44)33.97 ± 9.9032.57 ± 8.2033.10 ± 7.98
Baseline for Day 1800 cohort (n=54, 43, 42)33.85 ± 9.7932.39 ± 8.3133.01 ± 8.01
Baseline for Day 2160 cohort (n=45, 36, 35)33.61 ± 9.6133.26 ± 8.8532.80 ± 7.63
Baseline for Day 2520 cohort (n=38, 35, 33)33.72 ± 9.8533.41 ± 8.9333.95 ± 8.68
Baseline for Day 2880 cohort (n=33, 30, 31)33.74 ± 9.6033.38 ± 8.4533.43 ± 7.90
Baseline for Day 3060 cohort (n=17, 18, 16)37.52 ± 11.7134.63 ± 8.5735.47 ± 9.82
SecondaryMean Change From Baseline (BL) in the Role-Physical Domain of the SF-36 Over Time in OL Period

SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 55.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Reported as:
Mean · Units on a Scale
Mean Change From Baseline (BL) in the Role-Physical Domain of the SF-36 Over Time in OL Period
Units on a ScaleOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Change from BL at Day 360 (n=84, 66, 66)10.10 ± 1.326.97 ± 1.225.68 ± 1.51
Change from BL at Day 720 (n=73, 56, 53)9.69 ± 1.519.60 ± 1.499.03 ± 1.55
Change from BL at Day 1080 (n=64, 50, 49)8.73 ± 1.638.06 ± 1.6912.12 ± 1.86
Change from BL at Day 1440 (n=60, 46, 44)7.78 ± 1.6910.30 ± 1.6611.89 ± 1.76
Change from BL at Day 1800 (n=54, 43, 42)9.95 ± 1.857.57 ± 1.5011.11 ± 1.74
Change from BL at Day 2160 (n=45, 36, 35)10.37 ± 1.8610.41 ± 1.9211.65 ± 2.14
Change from BL at Day 2520 (n=38, 35, 33)9.49 ± 2.209.50 ± 1.949.43 ± 2.57
Change from BL at Day 2880 (n=33, 30, 31)11.79 ± 2.327.31 ± 1.8410.95 ± 2.32
Change from BL at Day 3060 (n=17, 18, 16)11.65 ± 3.534.32 ± 2.6310.61 ± 3.48
SecondaryMean Baseline Bodily Pain Domain of the SF-36 Over Time in OL Period

SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 58.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Reported as:
Mean · Units on a Scale
Mean Baseline Bodily Pain Domain of the SF-36 Over Time in OL Period
Units on a ScaleOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Baseline for Day 360 cohort (n=84, 67, 66)35.91 ± 8.5233.82 ± 7.6936.39 ± 7.98
Baseline for Day 720 cohort (n=73, 56, 53)36.10 ± 8.7634.23 ± 7.6335.93 ± 7.35
Baselinefor Day 1080 cohort (n=64, 50, 49)36.06 ± 8.7334.57 ± 7.8436.04 ± 7.48
Baseline for Day 1440 cohort (n=60, 46, 44)35.28 ± 8.5934.56 ± 7.9935.42 ± 7.37
Baseline for Day 1800 cohort (n=54, 43, 42)36.22 ± 8.9434.57 ± 8.2335.54 ± 7.27
Baseline for Day 2160 cohort (n=45, 36, 35)35.57 ± 9.3534.50 ± 8.2735.59 ± 7.65
Baseline for Day 2520 cohort (n=38, 35, 33)35.35 ± 9.4935.29 ± 8.3235.32 ± 7.73
Baseline for Day 2880 cohort (n=33, 30, 31)35.12 ± 9.6835.76 ± 8.2735.29 ± 8.03
Baseline for Day 3060 cohort (n=17, 18, 16)38.83 ± 9.6035.75 ± 7.8237.72 ± 8.69
SecondaryMean Change From BL in the Bodily Pain Domain of the SF-36 Over Time in OL Period

SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 57.

Time frame:
BL (Day 0); Day 360; Day 720; Day 1,080; Day 1,440; Day 1,800; Day 2,160; Day 2,520; Day 2,880; Day 3,060
Reported as:
Mean · Units on a Scale
Mean Change From BL in the Bodily Pain Domain of the SF-36 Over Time in OL Period
Units on a ScaleOL Abatacept: Original 10 mg / kg GroupOL Abatacept: Original 2 mg / kg GroupOL Abatacept: Original Placebo Group
Change from BL at Day 360 (n=84, 67, 66)10.35 ± 1.149.26 ± 1.074.12 ± 1.13
Change from BL at Day 720 (n=73, 56, 53)8.84 ± 1.369.40 ± 1.339.17 ± 1.42
Change from BL at Day 1,080 (n=64, 50, 49)9.02 ± 1.359.67 ± 1.559.48 ± 1.59
Change from BL at Day 1,440 (n=60, 46, 44)9.54 ± 1.3711.38 ± 1.5910.86 ± 1.61
Change from BL at Day 1,800 (n=54, 43, 42)9.08 ± 1.508.73 ± 1.6210.03 ± 1.64
Change from BL at Day 2,160 (n=45, 36, 35)10.27 ± 1.8312.11 ± 1.6610.83 ± 1.74
Change from BL at Day 2,520 (n=38, 35, 33)10.97 ± 1.9010.55 ± 1.6110.11 ± 1.76
Change from BL at Day 2,880 (n=33, 30, 31)11.68 ± 1.9910.08 ± 1.6610.86 ± 1.86
Change from BL at Day 3,060 (n=17, 18, 16)9.28 ± 3.776.45 ± 2.8510.52 ± 3.15
SecondaryMean BL General Health Domain of the SF-36 Over Time in OL Period

SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 60.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Reported as:
Mean · Units on a Scale
Mean BL General Health Domain of the SF-36 Over Time in OL Period
Units on a ScaleOL Abatacept: Original 10 mg / kg GroupOL Abatacept: Original 2 mg / kg GroupOL Abatacept: Original Placebo Group
BL (Day 0) for Day 360 cohort (n=84, 67, 66)37.11 ± 9.2335.87 ± 9.2337.45 ± 9.01
BL (Day 0) for Day 720 cohort (n=73, 56, 53)37.36 ± 9.3035.61 ± 8.9638.06 ± 8.26
BL (Day 0) for Day 1,080 cohort (n=64, 50, 49)37.55 ± 9.3835.78 ± 9.1337.45 ± 8.37
BL (Day 0) for Day 1,440 cohort (n=60, 46, 44)37.41 ± 9.1235.67 ± 8.8837.64 ± 8.60
BL (Day 0) for Day 1,800 cohort (n=54, 43, 42)38.08 ± 9.7535.60 ± 8.9837.78 ± 8.59
BL (Day 0) for Day 2,160 cohort (n=45, 37, 35)38.81 ± 9.9435.69 ± 8.8536.93 ± 8.65
BL (Day 0) for Day 2,520 cohort (n=38, 36, 33)39.25 ± 10.4036.17 ± 9.4036.98 ± 8.50
BL (Day 0) for Day 2,880 cohort (n=33, 30, 31)40.09 ± 10.4935.39 ± 8.5436.57 ± 8.54
BL (Day 0) for Day 3,060 cohort (n=18, 18, 16)41.37 ± 11.4933.88 ± 8.5836.84 ± 9.18
SecondaryMean Change From Baseline (BL) in the General Health Domain of the SF-36 Over Time in OL Period

SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 59.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Reported as:
Mean · Units on a Scale
Mean Change From Baseline (BL) in the General Health Domain of the SF-36 Over Time in OL Period
Units on a ScaleOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Change from BL at Day 360 (n=84, 67, 66)6.98 ± 0.906.08 ± 1.053.48 ± 0.71
Change from BL at Day 720 (n=73, 56, 53)5.96 ± 1.065.99 ± 1.245.09 ± 0.96
Change from BL at Day 1080 (n=64, 50, 49)6.18 ± 1.126.27 ± 1.075.63 ± 1.05
Change from BL at Day 1440 (n=60, 46, 44)5.84 ± 1.128.01 ± 0.914.80 ± 1.17
Change from BL at Day 1800 (n=54, 43, 42)6.52 ± 1.256.87 ± 1.263.97 ± 1.25
Change from BL at Day 2160 (n=45, 37, 35)5.27 ± 1.408.73 ± 1.305.38 ± 1.56
Change from BL at Day 2520 (n=38, 36, 33)6.42 ± 1.856.51 ± 1.215.38 ± 1.43
Change from BL at Day 2880 (n=33, 30, 31)6.37 ± 2.058.67 ± 1.455.61 ± 1.30
Change from BL at Day 3060 (n=18, 18, 16)5.09 ± 2.736.82 ± 2.213.88 ± 1.46
SecondaryMean Baseline Vitality Domain of the SF-36 Over Time in OL Period

SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 62.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Reported as:
Mean · Units on a Scale
Mean Baseline Vitality Domain of the SF-36 Over Time in OL Period
Units on a ScaleOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Baseline for Day 360 cohort (n=84, 67, 66)41.17 ± 8.2940.68 ± 8.8442.49 ± 9.81
Baseline for Day 720 cohort (n=73, 55, 53)41.15 ± 8.2941.22 ± 8.2543.25 ± 9.84
Baseline for Day 1080 cohort (n=63, 50, 49)40.65 ± 8.2441.72 ± 8.5642.58 ± 9.81
Baseline for Day 1440 cohort (n=59, 46, 44)40.84 ± 8.1741.85 ± 8.8143.08 ± 9.81
Baseline for Day 1800 cohort (n=54, 43, 42)41.09 ± 8.2741.40 ± 8.7243.42 ± 9.83
Baseline for Day 2160 cohort (n=45, 37, 35)41.66 ± 8.5940.93 ± 8.6542.77 ± 10.04
Baseline for Day 2520 cohort (n=38, 36, 33)41.66 ± 9.0341.43 ± 9.2642.74 ± 9.64
Baseline for Day 2880 cohort (n=33, 30, 31)42.12 ± 8.8040.22 ± 8.2242.34 ± 9.57
Baseline for Day 3060 cohort (n=18, 17, 16)44.06 ± 8.6641.12 ± 7.2942.40 ± 9.20
SecondaryMean Change From Baseline (BL) in the Vitality Domain of the SF-36 Over Time in OL Period

SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 61.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Reported as:
Mean · Units on a Scale
Mean Change From Baseline (BL) in the Vitality Domain of the SF-36 Over Time in OL Period
Units on a ScaleOL Abatacept: Original 10 mg /kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Change from BL at Day 360 (n=84, 67, 66)8.50 ± 1.024.91 ± 1.031.86 ± 1.04
Change from BL at Day 720 (n=73, 55, 53)7.77 ± 1.016.20 ± 1.274.69 ± 1.20
Change from BL at Day 1080 (n=63, 50, 49)7.73 ± 1.186.30 ± 1.166.46 ± 1.23
Change from BL at Day 1440 (n=59, 46, 44)6.00 ± 1.257.61 ± 1.234.73 ± 1.62
Change from BL at Day 1800 (n=54, 43, 42)7.44 ± 1.416.33 ± 1.143.49 ± 1.70
Change from BL at Day 2160 (n=45, 37, 35)8.15 ± 1.537.10 ± 1.184.60 ± 1.96
Change from BL at Day 2520 (n=38, 36, 33)6.64 ± 1.986.86 ± 1.213.82 ± 2.03
Change from BL at Day 2880 (n=33, 30, 31)6.65 ± 1.867.10 ± 1.344.76 ± 1.70
Change from BL at Day 3060 (n=18, 17, 16)4.60 ± 3.026.68 ± 2.213.99 ± 2.34
SecondaryMean Baseline Social Functioning Domain of the SF-36 Over Time in OL Period

SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 64.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Reported as:
Mean · Units on a Scale
Mean Baseline Social Functioning Domain of the SF-36 Over Time in OL Period
Units on a ScaleOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo Group
Baseline for Day 360 cohort (n=84, 67, 66)38.59 ± 10.9934.45 ± 10.5238.14 ± 10.91
Baseline for Day 720 cohort (n=73, 56, 53)39.37 ± 11.1335.04 ± 9.8139.11 ± 10.74
Baseline for Day 1080 cohort (n=64, 50, 49)38.99 ± 11.0434.77 ± 9.2239.08 ± 10.71
Baseline for Day 1440 cohort (n=60, 46, 44)38.77 ± 11.0435.19 ± 9.3638.88 ± 11.05
Baseline for Day 1800 cohort (n=54, 43, 42)38.84 ± 11.5234.92 ± 9.5439.04 ± 11.03
Baseline for Day 2160 cohort (n=45, 36, 35)39.16 ± 11.4535.42 ± 9.5438.06 ± 10.97
Baseline for Day 2520 cohort (n=38, 35, 33)39.42 ± 11.8235.11 ± 9.8538.88 ± 10.93
Baseline for Day 2880 cohort (n=33, 30, 31)39.54 ± 12.1436.33 ± 8.8038.40 ± 10.75
Baseline for Day 3060 cohort (n=17, 18, 16)42.77 ± 11.6636.33 ± 8.7838.82 ± 12.52
SecondaryMean Change From Baseline (BL) in the Social Functioning Domain of the SF-36 Over Time in OL Period

SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 63.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Reported as:
Mean · Units on a Scale
Mean Change From Baseline (BL) in the Social Functioning Domain of the SF-36 Over Time in OL Period
Units on a ScaleOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Change from BL at Day 360 (n=84, 67, 66)8.47 ± 1.258.02 ± 1.114.44 ± 1.12
Change from BL at Day 720 (n=73, 56, 53)6.62 ± 1.398.43 ± 1.356.86 ± 1.28
Change from BL at Day 1080 (n=64, 50, 49)5.94 ± 1.208.25 ± 1.057.87 ± 1.38
Change from BL at Day 1440 (n=60, 46, 44)6.24 ± 1.519.56 ± 1.398.02 ± 1.82
Change from BL at Day 1800 (n=54, 43, 42)8.65 ± 1.496.69 ± 1.566.59 ± 1.86
Change from BL at Day 2160 (n=45, 36, 35)9.53 ± 1.589.95 ± 1.297.13 ± 2.08
Change from BL at Day 2520 (n=38, 35, 33)5.00 ± 2.2410.70 ± 1.405.76 ± 2.19
Change from BL at Day 2880 (n=33, 30, 31)7.90 ± 1.996.69 ± 1.705.25 ± 1.93
Change from BL at Day 3060 (n=17, 18, 16)6.07 ± 2.986.03 ± 2.234.07 ± 3.03
SecondaryMean Baseline Role-Emotional Domain of the SF-36 Over Time in OL Period

SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 66.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Reported as:
Mean · Units on a Scale
Mean Baseline Role-Emotional Domain of the SF-36 Over Time in OL Period
Units on a ScaleOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Baseline for Day 360 cohort (n=84, 67, 64)40.29 ± 14.0936.63 ± 14.3038.88 ± 14.28
Baseline for Day 720 cohort (n=73, 56, 53)40.19 ± 14.0436.15 ± 14.0838.84 ± 14.68
Baseline for Day 1080 cohort (n=64, 50, 49)39.21 ± 13.9237.01 ± 14.0939.43 ± 14.76
Baseline for Day 1440 cohort (n=60, 46, 44)38.84 ± 13.9037.48 ± 14.0239.30 ± 14.81
Baseline for Day 1800 cohort (n=54, 43, 42)38.76 ± 13.9736.97 ± 14.1939.29 ± 14.76
Baseline for Day 2160 cohort (n=45, 36, 35)38.72 ± 14.2937.78 ± 14.0239.09 ± 14.97
Baseline for Day 2520 cohort (n=38, 35, 33)39.54 ± 14.8537.88 ± 14.2140.34 ± 14.67
Baseline for Day 2880 cohort (n=33, 30, 31)38.10 ± 14.6236.73 ± 14.2939.37 ± 14.62
Baseline for Day 3060 cohort (n=17, 18, 16)40.47 ± 14.9337.78 ± 14.4544.15 ± 14.12
SecondaryMean Change From Baseline (BL) in the Role-Emotional Domain of the SF-36 Over Time in OL Period

SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 65.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Reported as:
Mean · Units on a Scale
Mean Change From Baseline (BL) in the Role-Emotional Domain of the SF-36 Over Time in OL Period
Units on a ScaleOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Change from BL at Day 360 (n=84, 67, 64)8.03 ± 1.587.55 ± 2.053.79 ± 1.94
Change from BL at Day 720 (n=73, 56, 53)6.93 ± 1.688.28 ± 2.296.36 ± 1.97
Change from BL at Day 1080 (n=64, 50, 49)5.76 ± 1.884.64 ± 2.247.95 ± 2.27
Change from BL at Day 1440 (n=60, 46, 44)6.67 ± 1.868.24 ± 2.317.18 ± 2.56
Change from BL at Day 1800 (n=54, 43, 42)7.41 ± 2.044.16 ± 2.484.51 ± 2.19
Change from BL at Day 2160 (n=45, 36, 35)7.84 ± 2.167.61 ± 2.406.47 ± 2.87
Change from BL at Day 2520 (n=38, 35, 33)5.82 ± 2.348.43 ± 2.925.75 ± 2.64
Change from BL at Day 2880 (n=33, 30, 31)8.94 ± 2.728.78 ± 2.324.76 ± 3.04
Change from BL at Day 3060 (n=17, 18, 16)9.92 ± 4.095.85 ± 3.920.66 ± 4.66
SecondaryMean Baseline Mental Health Domain of the SF-36 Over Time in OL Period

SF-36 = PCS \& MCS \& 8 individual indices (physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health). Subscales were scored using norm-based methods that standardized scores to a mean of 50 \& a standard deviation of 10 in the general population. Scores range from 0 to 100, with a higher score indicating better quality of life. Time-matched BL \& post-BL values are presented for each post-BL visit \& represent only that cohort with measurements available at that assessment. Change from BL data are presented in Outcome Measure 68.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Reported as:
Mean · Units on a Scale
Mean Baseline Mental Health Domain of the SF-36 Over Time in OL Period
Units on a ScaleOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Baseline for Day 360 cohort (n=84, 67, 66)44.66 ± 11.9441.29 ± 12.2842.35 ± 11.62
Baseline for Day 720 cohort (n=73, 55, 53)44.53 ± 12.1940.49 ± 12.7241.99 ± 11.58
Baseline for Day 1080 cohort (n=63, 50, 49)44.13 ± 11.8240.81 ± 12.6641.44 ± 11.55
Baseline for Day 1440 cohort (n=59, 46, 44)44.24 ± 11.0941.11 ± 12.6141.60 ± 11.77
Baseline for Day 1800 cohort (n=54, 43, 42)44.13 ± 11.1440.78 ± 12.3941.50 ± 11.78
Baseline for Day 2160 cohort (n=45, 37, 35)44.79 ± 11.1840.50 ± 12.1740.89 ± 11.05
Baselinefor Day 2520 cohort (n=38, 36, 33)45.54 ± 11.1042.05 ± 12.5441.06 ± 11.44
Baseline for Day 2880 cohort (n=33, 30, 31)44.87 ± 9.9239.77 ± 10.7640.24 ± 10.92
Baseline for Day 3060 cohort (n=18, 17, 16)44.89 ± 11.8539.49 ± 11.6240.18 ± 12.07
SecondaryMean Change From Baseline (BL) in the Mental Health Domain of the SF-36 Over Time in OL Period

SF-36=2 summaries (PCS \& MCS) \& 8 individual indices including physical function, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, \& mental health. All subscales were scored using norm-based methods that standardized the scores to a mean of 50 \& a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Mean change from BL = value at post-BL OL time point-value and BL OL time point. Baseline data for these time-matched cohorts are presented in Outcome Measure 67.

Time frame:
Baseline (Day 0) and Days 360, 720, 1080, 1440, 1800, 2160, 2520, 2880, and 3060
Reported as:
Mean · Units on a Scale
Mean Change From Baseline (BL) in the Mental Health Domain of the SF-36 Over Time in OL Period
Units on a ScaleOL Abatacept: Original 10 mg/kgOL Abatacept: Original 2 mg/kgOL Abatacept: Original Placebo
Change from BL at Day 360 (n=84, 67, 66)5.41 ± 1.105.74 ± 1.142.60 ± 1.13
Change from BL at Day 720 (n=73, 55, 53)4.22 ± 1.185.49 ± 1.294.59 ± 1.50
Change from BL at Day 1080 (n=63, 50, 49)4.62 ± 1.035.41 ± 1.485.54 ± 1.59
Change from BL at Day 1440 (n=59, 46, 44)4.81 ± 1.145.96 ± 1.245.59 ± 1.93
Change from BL at Day 1800 (n=54, 43, 42)4.47 ± 1.345.44 ± 1.453.15 ± 1.80
Change from BL at Day 2160 (n=45, 37, 35)5.82 ± 1.335.96 ± 1.265.29 ± 1.94
Change from BL at Day 2520 (n=38, 36, 33)3.15 ± 1.926.06 ± 1.506.33 ± 1.94
Change from BL at Day 2880 (n=33, 30, 31)4.96 ± 1.716.30 ± 1.606.78 ± 1.98
Change from BL at Day 3060 (n=18, 17, 16)2.65 ± 2.354.68 ± 2.596.99 ± 2.68

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aba 10mg/kg+MTX—17/115 (14.8%)96/115 (83.5%)
Aba 2mg/kg+MTX—19/105 (18.1%)98/105 (93.3%)
Abatacept (LT)—117/219 (53.4%)200/219 (91.3%)
Placebo+MTX—21/119 (17.6%)108/119 (90.8%)
Most frequent serious events
Showing 10 of 239
Most frequent serious events
EventAba 10mg/kg+MTXAba 2mg/kg+MTXAbatacept (LT)Placebo+MTX
RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders0/1151/10518/2192/119
CHEST PAINGeneral disorders1/1154/1052/2190/119
PNEUMONIAInfections and infestations0/1150/1058/2191/119
OSTEOARTHRITISMusculoskeletal and connective tissue disorders0/1150/1057/2190/119
ARTHRALGIAMusculoskeletal and connective tissue disorders0/1150/1056/2190/119
BASAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1150/1055/2190/119
DEEP VEIN THROMBOSISVascular disorders0/1150/1054/2190/119
CHOLELITHIASISHepatobiliary disorders1/1150/1054/2190/119
HIP FRACTUREInjury, poisoning and procedural complications0/1150/1054/2191/119
BACK PAINMusculoskeletal and connective tissue disorders0/1150/1054/2190/119
Most frequent other events
Showing 10 of 65
Most frequent other events
EventAba 10mg/kg+MTXAba 2mg/kg+MTXAbatacept (LT)Placebo+MTX
RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders35/11550/105100/21955/119
NASOPHARYNGITISInfections and infestations17/11519/10576/21911/119
BACK PAINMusculoskeletal and connective tissue disorders10/1159/10565/2199/119
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations13/11510/10558/2199/119
COUGHRespiratory, thoracic and mediastinal disorders16/11510/10552/21915/119
BRONCHITISInfections and infestations9/1157/10551/2195/119
SINUSITISInfections and infestations5/1157/10550/21910/119
URINARY TRACT INFECTIONInfections and infestations3/1152/10548/2193/119
HYPERTENSIONVascular disorders8/11512/10545/2199/119
HEADACHENervous system disorders16/11517/10543/21919/119

Baseline characteristics

Age Continuous
Age Continuous(years)Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + MethotrexateTotal
Mean55.8 ± 12.554.4 ± 11.354.7 ± 12.055.0 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + MethotrexateTotal
Female866679231
Male293940108
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + MethotrexateTotal
White10091104295
Black6039
Other9141235
Weight
Weight(Kg)Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + MethotrexateTotal
Mean77.8 ± 18.678.7 ± 21.479.9 ± 17.678.8 ± 19.2
Rheumatoid Factor Status
Rheumatoid Factor Status(Participants)Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + MethotrexateTotal
Negative14152756
Positive999090279
Number of Tender Joints
Number of Tender Joints(Joints)Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + MethotrexateTotal
Mean30.8 ± 12.228.2 ± 12.029.2 ± 13.029.4 ± 12.4
Number of Swollen Joints
Number of Swollen Joints(Joints)Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + MethotrexateTotal
Mean21.3 ± 8.420.2 ± 8.921.8 ± 8.821.1 ± 8.7
C-Reactive Protein (CRP) Serum Level
C-Reactive Protein (CRP) Serum Level(mg/dL)Double-Blind (DB) Abatacept 10 mg/kg + Methotrexate (MTX)Double-Blind (DB) Abatacept 2 mg/kg + MethotrexateDouble-Blind (DB) Placebo + MethotrexateTotal
Mean2.9 ± 2.83.2 ± 2.53.2 ± 3.23.1 ± 2.9

1 further baseline measures are reported on the registry.

08

Study locations

57 sites
  • Local Institution
    Birmingham, Alabama, United States
  • Local Institution
    Huntsville, Alabama, United States
  • Local Institution
    Long Beach, California, United States
  • Local Institution
    Highlands Ranch, Colorado, United States
  • Local Institution
    Largo, Florida, United States
  • Local Institution
    Titusville, Florida, United States
  • Local Institution
    West Palm Beach, Florida, United States
  • Local Institution
    Rome, Georgia, United States
  • Local Institution
    Chicago, Illinois, United States
  • Local Institution
    Wichita, Kansas, United States
  • Local Institution
    Cumberland, Maryland, United States
  • Local Institution
    Springfield, Massachusetts, United States
  • Local Institution
    Worcester, Massachusetts, United States
  • Local Institution
    Duluth, Minnesota, United States
  • Local Institution
    Lincoln, Nebraska, United States
  • Local Institution
    Albuquerque, New Mexico, United States
  • Local Institution
    Los Alamos, New Mexico, United States
  • Local Institution
    Albany, New York, United States
  • Local Institution
    Binghamton, New York, United States
  • Local Institution
    Bronx, New York, United States
  • Local Institution
    Portland, Oregon, United States
  • Local Institution
    Duncansville, Pennsylvania, United States
  • Local Institution
    Sellersville, Pennsylvania, United States
  • Local Institution
    Amarillo, Texas, United States
  • Local Institution
    Austin, Texas, United States
  • Local Institution
    Dallas, Texas, United States
  • Local Institution
    Quilmes, Burenos Aires, Argentina
  • Local Institution
    Buenos Aries, Argentina
  • Local Institution
    Adelaide, South Australia, Australia
  • Local Institution
    Malvern, Victoria, Australia
  • Local Institution
    Perth, Western Australia, Australia
  • Local Institution
    Antwerpen, Belgium
  • Local Institution
    Bruxelles, Belgium
  • Local Institution
    Gent, Belgium
  • Local Institution
    Leuven, Belgium
  • Local Institution
    Mons, Belgium
  • Local Institution
    Edmonton, Alberta, Canada
  • Local Institution
    Ottawa, Ontario, Canada
  • Local Institution
    Toronto, Ontario, Canada
  • Local Institution
    Montreal, Quebec, Canada
  • Local Institution
    Sherbrooke, Quebec, Canada
  • Local Institution
    Ste-Foy, Quebec, Canada
  • Local Institution
    St. John, Canada
  • Local Institution
    Montpellier, Cedex, France
  • Local Institution
    Strasbourg, Cedex, France
  • Local Institution
    Paris, France
  • Local Institution
    Berlin, Germany
  • Local Institution
    Freiburg, Germany
  • Local Institution
    Jena, Germany
  • Local Institution
    Cork, Ireland
  • Local Institution
    Nijmegen, Netherlands
  • Local Institution
    Muckleneuk, Gauteng, South Africa
  • Local Institution
    Cape Town, Western Cape, South Africa
  • Local Institution
    Cambridge, Cambridgeshire, United Kingdom
  • Local Institution
    Manchester, Greater Manchester, United Kingdom
  • Local Institution
    Maidstone, Kent, United Kingdom
  • Local Institution
    Leeds, Yorkshire, United Kingdom
09

References and documents

Publications

  • Westhovens R, Kremer JM, Emery P, Russell AS, Alten R, Barre E, Dougados M. Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study. Clin Exp Rheumatol. 2014 Jul-Aug;32(4):553-62. Epub 2014 Jul 8. PubMed 25005467 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2000, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2012, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 13, 2005
Start
Oct 2000
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results first posted
Jun 1, 2012
Last update
Jun 1, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00162266
Responsible party
Sponsor
First posted
Sep 13, 2005
Start date
Oct 2000
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
Jun 1, 2012
Last update
Jun 1, 2012

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion